WO2022179093A1 - 用于治疗自身免疫性疾病的多肽 - Google Patents

用于治疗自身免疫性疾病的多肽 Download PDF

Info

Publication number
WO2022179093A1
WO2022179093A1 PCT/CN2021/119376 CN2021119376W WO2022179093A1 WO 2022179093 A1 WO2022179093 A1 WO 2022179093A1 CN 2021119376 W CN2021119376 W CN 2021119376W WO 2022179093 A1 WO2022179093 A1 WO 2022179093A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
polypeptide
variant
protein
acid residues
Prior art date
Application number
PCT/CN2021/119376
Other languages
English (en)
French (fr)
Inventor
孟颂东
胡柳益
徐玉秀
Original Assignee
佛山热休生物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 佛山热休生物技术有限公司 filed Critical 佛山热休生物技术有限公司
Publication of WO2022179093A1 publication Critical patent/WO2022179093A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Definitions

  • the present invention relates to the field of disease treatment.
  • the present invention provides polypeptides or variants thereof, comprising such polypeptides or Variant fusion proteins, and medicinal uses of such polypeptides or variants and fusion proteins thereof.
  • the present invention also relates to pharmaceutical compositions useful for treating autoimmune diseases (eg, systemic lupus erythematosus, type 1 diabetes, rheumatoid arthritis, ankylosing spondylitis) or alleviating one or more symptoms of autoimmune diseases , which comprises a polypeptide of the present invention or a variant or fusion protein thereof.
  • autoimmune diseases eg, systemic lupus erythematosus, type 1 diabetes, rheumatoid arthritis, ankylosing spondylitis
  • alleviating one or more symptoms of autoimmune diseases which comprises a polypeptide of the present invention or a variant or fusion protein thereof.
  • Autoimmune diseases are a series of diseases in which organ and tissue damage is caused by impairment or loss of self-tolerance of the immune system. Including such as systemic lupus erythematosus (SLE), type 1 diabetes, rheumatoid arthritis (RA), ankylosing spondylitis (AS) and so on.
  • SLE systemic lupus erythematosus
  • RA rheumatoid arthritis
  • AS ankylosing spondylitis
  • the immune function is abnormally activated, attacking the normal tissues and organs of the body, and can affect multiple systems in the body.
  • Systemic lupus erythematosus English systemic lupus erythematosus, referred to as SLE.
  • Systemic lupus erythematosus is an autoimmune disease that usually occurs in women between the ages of 20 and 40. The etiology of the disease has not yet been clarified.
  • a large number of studies have shown that genetic, endocrine, infection, immune abnormalities and some environmental factors may be related to the pathogenesis of the disease. Under the interaction of various factors such as genetic factors, environmental factors, and estrogen levels, the patient's T lymphocytes decrease, suppressor T cell function decreases, and B cells hyperproliferate, resulting in a large number of autoantibodies that bind to the corresponding autoantigens in the body.
  • the corresponding immune complexes are formed and deposited in the skin, joints, small blood vessels, glomeruli, etc., causing acute and chronic inflammation and tissue necrosis (such as lupus nephritis), or antibodies directly interact with tissue cell antigens, causing cell destruction (such as red blood cells). , lymphocyte and platelet wall-specific antigens combined with the corresponding autoantibodies, causing hemolytic anemia, lymphopenia and thrombocytopenia, respectively), resulting in multi-system damage to the body.
  • SLE The diagnosis of SLE mainly relies on clinical manifestations, laboratory tests, histopathology, and imaging studies.
  • laboratory tests such as hematological abnormalities, immunological abnormalities and positive autoantibodies were clearly included in the diagnostic criteria.
  • routine blood tests may show symptoms such as anemia, decreased white blood cell count, and low platelet counts; urinalysis may show proteinuria, hematuria, and cellular and granular casts.
  • the routine detection items of systemic lupus erythematosus-related autoantibodies mainly include antinuclear antibody (ANA), anti-double-stranded deoxyribonucleic acid antibody (anti-dsDNA antibody), anti-soluble antigen antibody (anti-ENA antibody) (including anti-Sm, Anti-U1RNP, anti-SSA/Ro, anti-SSB/La, anti-rRNP, anti-Scl-70 and anti-Jo-1, etc.), anti-nucleosome antibody and anti-phospholipid antibody, etc.
  • immunological abnormalities and positive autoantibodies include: anti-Sm antibody, anti-dsDNA antibody, antiphospholipid antibody and ANA positive.
  • T1DM Type 1 diabetes, English type 1 diabetes mellitus, referred to as T1DM.
  • T1DM is an autoimmune disease caused by the destruction of beta cells in the pancreatic islets by the immune system. T1DM can occur at any age, but is usually most common in adolescence and begins around puberty. Studies have shown that both genetic and environmental factors play a role in the pathogenesis of T1DM, but the exact etiology of T1DM is unclear. At present, the main treatment for T1MD is still lifelong insulin injection to control blood sugar.
  • RA Rheumatoid arthritis, English rheumatoid arthritis, referred to as RA.
  • RA is characterized by an imbalance of the immune system leading to overproduction of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF) interleukin 1 (IL-1) and deficiency of anti-inflammatory cytokines such as IL-10, IL-11 .
  • IL-1 tumor necrosis factor alpha
  • IL-10 interleukin 1
  • RA is characterized by inflammation of the synovium, which progresses to cartilage destruction, bone erosion, and subsequent joint deformation.
  • the primary symptoms of RA are joint inflammation, swelling, difficulty moving, and pain.
  • enzymes produced by inflammatory cells digest bone and cartilage. Long-term damage results in chronic pain, loss of function, deformation, and even shortened lifespan of the joints.
  • anti-TNF therapy has made good progress in the treatment of RA in recent years, it can only be used in some patients, and at least one third of RA
  • Ankylosing spondylitis English ankylosing spondylitis, referred to as AS, is a chronic, progressive, chronic inflammatory disease involving the axial and peripheral joints. It mainly affects the sacroiliac joints, spinal joints and paravertebral tissues of the pelvis. The main symptoms are low back pain, spinal stiffness and limited range of motion. The disease generally first invades the sacroiliac joints, and focuses on the spine, eventually leading to bony ankylosis of the spine, and can be accompanied by different levels of damage to the heart, eyes, lungs, and other organs.
  • HSPs Heat shock proteins
  • HSP90 Human heat shock protein 90 family
  • HSP90 includes four members, HSP90 ⁇ , HSP90 ⁇ , gp96 (grp94) and Trap-1.
  • gp96 is a representative of the endoplasmic reticulum HSP90 family. It is highly homologous to cytoplasmic HSP90.
  • molecular chaperones involved in the folding and assembly of newly synthesized proteins
  • other intracellular peptide proteins especially denatured proteins. It participates in the process of anti-injury, repair and heat tolerance of cells; participates in the process of proteolysis; combines with antigen peptides, processes and presents tumor antigens and maintains the stability of the intracellular environment; it has effects on cell growth, development, differentiation and death. certain adjustment.
  • full-length gp96 can activate regulatory T cells (Treg), it also has strong activation effector CD4 + T, CD8 + T cells, B cells and other functions, and cannot specifically target regulatory T cells alone. Therefore, full-length gp96 may activate the immune system in the treatment of autoimmune diseases, resulting in poor treatment effect, and may even aggravate autoimmune diseases.
  • a specific polypeptide fragment of full-length gp96 has the activity of specifically targeting regulatory T cells alone, and not targeting effector T cells and B cells, so it is especially suitable for self-targeting.
  • the treatment of immune diseases has important clinical application value.
  • the present invention provides an isolated polypeptide or a variant thereof, wherein the polypeptide consists of at least 136 consecutive amino acid residues of gp96 protein, and comprises: amino acid residues 578-713 of gp96 protein ;
  • the variant differs from the polypeptide from which it is derived only by the substitution, deletion or addition of one or several (eg, 1, 2, 3, 4 or 5) amino acid residues, and The biological function of the polypeptide from which it is derived is preserved.
  • the biological functions of the polypeptides of the invention or variants thereof include, but are not limited to, induction of regulatory T cell activation, no or substantially no induction of effector T cell and B cell activation, treatment of autoimmune diseases or self-alleviation One or more symptoms of an immune disorder, decreased levels of anti-double-stranded DNA antibodies, decreased urine protein levels, and/or decreased blood sugar.
  • the first amino acid (eg, methionine (M)) encoded by the initiation codon is often the first amino acid in the generated polypeptide chain.
  • the polypeptides of the present invention or variants thereof include not only amino acid sequences that do not contain an amino acid (eg, methionine) encoded by an initiation codon at their N-terminus, but also include amino acids that contain an initiation codon-encoded N-terminus at their N-terminus.
  • the gp96 protein is of human origin. In certain embodiments, the gp96 protein has the amino acid sequence set forth in SEQ ID NO:7.
  • the isolated polypeptides of the invention consist of no more than 254 contiguous amino acid residues of gp96 protein, eg, no more than 250, 240, 230, 226, 224, 220, 210, 200, 196, 194, 190, 180, 170, 166, 164, 160, 150, 140 or 136 contiguous amino acid residues.
  • the variant differs from the polypeptide from which it is derived only by substitution of 1 or a few (eg, 1, 2, 3, 4, or 5) amino acid residues, Deletions or additions, the substitutions are conservative substitutions.
  • the variant differs from the polypeptide from which it is derived by only one, two, or three amino acid residue substitutions, deletions, or additions.
  • the replacement comprises replacing the amino acid residue with alanine (A).
  • the polypeptide of the invention comprises: amino acid residues 578-713, amino acid residues 578-743, amino acid residues 578-773, amino acid residues 578-803 of the gp96 protein base, amino acid residues 550-713, amino acid residues 550-743, amino acid residues 550-773, or amino acid residues 550-803.
  • the isolated polypeptide comprises or consists of an amino acid sequence selected from the group consisting of: SEQ ID NOs: 30, 31, 32, 33, 37, 42, 43, 44.
  • the sequence shown here contains a methionine encoded by the initiation codon at its N-terminus. It will be understood by those skilled in the art that the isolated polypeptide may also comprise, or consist of, the above-mentioned amino acid sequence that does not contain the methionine encoded by the initiation codon at its N-terminus.
  • the variant comprises or consists of an amino acid sequence selected from the group consisting of SEQ ID NOs: 55-62.
  • the sequence shown here contains a methionine encoded by the initiation codon at its N-terminus. It will be understood by those skilled in the art that the variant may also comprise, or consist of, the above-mentioned amino acid sequence which does not contain at its N-terminus the methionine encoded by the initiation codon.
  • the present invention provides a fusion protein comprising an isolated polypeptide (or variant thereof) of the present invention and an additional polypeptide.
  • the additional polypeptide is selected from a protein tag, a targeting moiety, or any combination thereof.
  • protein tags are well known in the art, examples of which include, but are not limited to, His, Flag, GST, MBP, HA, Myc, GFP, or biotin, and those skilled in the art know how to , detection or tracking) to select an appropriate protein tag.
  • targeting moiety refers to a domain capable of directing the polypeptide of the present invention (or variant thereof) to a desired location, which may be a specific tissue, a specific cell, Even specific intracellular locations (eg nucleus, ribosome, endoplasmic reticulum, lysosome or peroxisome).
  • a desired location which may be a specific tissue, a specific cell, Even specific intracellular locations (eg nucleus, ribosome, endoplasmic reticulum, lysosome or peroxisome).
  • the targeting moiety comprises a ligand, receptor or antibody or a binding domain thereof.
  • the additional polypeptide is optionally linked to the N-terminus or C-terminus of the polypeptide of the invention (or variant thereof) via a linker.
  • the linker is a sequence comprising one or more (eg, 1, 2, 3, 4 or 5) amino acids (eg, Gly or Ser).
  • polypeptide of the present invention or its variant or fusion protein is not limited by its production method, for example, it can be produced by genetic engineering methods (recombinant technology) or chemical synthesis methods.
  • the invention provides an isolated nucleic acid molecule comprising a nucleotide sequence encoding a polypeptide of the invention or a variant or fusion protein thereof.
  • the isolated nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: (i) the sequence set forth in any of SEQ ID NOs: 13-16, 20, 25-27, 47-54 (ii) a sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% sequence identity compared to the sequence of (i); (iii) ) a sequence that hybridizes under stringent conditions to a sequence described in (i) or (ii); or (iv) the complement of a sequence described in (i) or (ii).
  • the present invention also provides a vector comprising the isolated nucleic acid molecule as described above.
  • the vector of the present invention may be a cloning vector or an expression vector.
  • the vectors of the present invention are, for example, plasmids, cosmids, phages, cosmids, and the like.
  • the present invention also provides host cells comprising the isolated nucleic acid molecules or vectors of the present invention.
  • host cells include, but are not limited to, prokaryotic cells such as E. coli cells, and eukaryotic cells such as yeast cells, insect cells (eg, Sf9 cells), plant cells, and animal cells (eg, mammalian cells, eg, mouse cells, human cells) Wait).
  • the present invention also provides a method for preparing a polypeptide of the present invention, or a variant or fusion protein thereof, comprising culturing a host of the present invention under conditions that permit expression of the polypeptide or variant or fusion protein thereof cells, and recovering the polypeptide or variant or fusion protein thereof from the cultured host cell culture.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an isolated polypeptide (or variant thereof), fusion protein, isolated nucleic acid molecule, vector or host cell of the present invention, and a pharmaceutically acceptable carrier and/or excipients.
  • the pharmaceutical composition comprises one or more of the isolated polypeptides (or variants thereof) or fusion proteins of the invention.
  • the pharmaceutical composition optionally further comprises an additional pharmaceutically active agent, eg, a drug having activity in the treatment of autoimmune diseases.
  • the additional pharmaceutically active agent is selected from anti-inflammatory drugs or immunosuppressive agents, eg, non-steroidal anti-inflammatory drugs, steroidal anti-inflammatory drugs, antibodies or antagonists of pro-inflammatory cytokines, anti-inflammatory drugs inflammatory cytokines, etc.
  • the inventors of the present application discovered for the first time that the C-terminal domain of gp96 or its active fragments can specifically activate regulatory T cells without activating the activity of effector T cells and B cells, so it is especially suitable for the treatment of autoimmune diseases.
  • the present invention also relates to the C-terminal domain (ie, the C-terminal homodimerization domain) of gp96, or an active fragment or variant thereof, or an isolated polypeptide of the present invention (or a variant thereof) ), fusion protein, isolated nucleic acid molecule, vector, host cell or pharmaceutical composition for preventing and/or treating autoimmune disease or alleviating one or more symptoms of autoimmune disease in a subject, or reducing The level of anti-double-stranded DNA antibody, or the use of reducing the level of urinary protein, or reducing blood sugar, or the use in the preparation of a medicament for the prevention and/or treatment of an autoimmune disease or alleviation in a subject One or more symptoms of an autoimmune disease, or decreased levels of anti-double-stranded DNA antibodies, or decreased levels of urinary protein, or decreased blood sugar.
  • the C-terminal domain consists of amino acid residues 550-803 of the gp96 protein. In certain embodiments, the C-terminal domain has the sequence set forth in SEQ ID NO:30.
  • the active fragment or variant thereof of the C-terminal domain of gp96 is selected from the isolated polypeptides of the invention or variants thereof.
  • the medicament comprises one or more of the C-terminal domain of gp96 or an active fragment or variant thereof, an isolated polypeptide (or variant thereof) or a fusion protein of the invention .
  • the autoimmune disease may be selected from systemic lupus erythematosus, type 1 diabetes, rheumatoid arthritis, ankylosing spondylitis, multiple sclerosis, psoriasis, inflammatory bowel disease, Ulcerative colitis, Crohn's disease, myasthenia gravis, or polymyositis.
  • the medicament is for preventing and/or treating systemic lupus erythematosus or alleviating one or more symptoms of systemic lupus erythematosus (eg, reducing levels of anti-double-stranded DNA antibodies, and/or reducing urinary protein levels).
  • the medicament is for preventing and/or treating type 1 diabetes or alleviating one or more symptoms of type 1 diabetes (eg, lowering blood sugar).
  • the medicament is for preventing and/or treating rheumatoid arthritis or alleviating one or more symptoms of rheumatoid arthritis (eg, reducing joint swelling, tenderness, and/or pain).
  • the medicament is for preventing and/or treating ankylosing spondylitis or alleviating one or more symptoms of ankylosing spondylitis (eg, low back pain, spinal stiffness, and/or arthritis).
  • the subject may be a mammal, such as a human or a murine.
  • the subject has or is suspected of having, or is at risk of having, an autoimmune disease.
  • the subject has or is suspected of having, or is at risk of having, systemic lupus erythematosus.
  • the subject has or is suspected of having type 1 diabetes, or is at risk of developing such a disease.
  • the subject has or is suspected of having, or is at risk of having, rheumatoid arthritis.
  • the subject has or is suspected of having, or is at risk of having, ankylosing spondylitis.
  • the present invention also provides for preventing and/or treating an autoimmune disease or alleviating one or more symptoms of an autoimmune disease, or reducing the level of anti-double-stranded DNA antibodies, in a subject, or reducing the level of urinary protein, or reducing blood sugar, the method comprising administering to a subject in need thereof the C-terminal domain of gp96 or an active fragment or variant thereof, or an isolated polypeptide of the invention (or variants thereof), fusion proteins, isolated nucleic acid molecules, vectors, host cells or pharmaceutical compositions.
  • the C-terminal domain consists of amino acid residues 550-803 of the gp96 protein. In certain embodiments, the C-terminal domain has the sequence set forth in SEQ ID NO:30.
  • the active fragment or variant thereof of the C-terminal domain of gp96 is selected from the isolated polypeptides of the invention or variants thereof.
  • the subject is administered one of the C-terminal domain of gp96 or an active fragment or variant thereof, an isolated polypeptide (or variant thereof) or a fusion protein of the invention or more.
  • the autoimmune disease may be selected from systemic lupus erythematosus, type 1 diabetes, rheumatoid arthritis, ankylosing spondylitis, multiple sclerosis, psoriasis, inflammatory bowel disease, Ulcerative colitis, Crohn's disease, myasthenia gravis, or polymyositis.
  • the methods are for preventing and/or treating systemic lupus erythematosus or alleviating one or more symptoms of systemic lupus erythematosus (eg, reducing levels of anti-double-stranded DNA antibodies, and/or reducing urinary protein levels).
  • the methods are for preventing and/or treating type 1 diabetes or alleviating one or more symptoms of type 1 diabetes (eg, lowering blood sugar).
  • the methods are for preventing and/or treating rheumatoid arthritis or alleviating one or more symptoms of rheumatoid arthritis (eg, reducing joint swelling, tenderness, and/or pain).
  • the methods are for preventing and/or treating ankylosing spondylitis or alleviating one or more symptoms of ankylosing spondylitis (eg, low back pain, spinal stiffness, and/or arthritis).
  • the subject may be a mammal, such as a human or a murine.
  • the subject has or is suspected of having, or is at risk of having, an autoimmune disease.
  • the subject has or is suspected of having, or is at risk of having, systemic lupus erythematosus.
  • the subject has or is suspected of having type 1 diabetes, or is at risk of developing such a disease.
  • the subject has or is suspected of having, or is at risk of having, rheumatoid arthritis.
  • the subject has or is suspected of having, or is at risk of having, ankylosing spondylitis.
  • polypeptide (or variant thereof), fusion protein or pharmaceutical composition of the present invention, or the C-terminal domain of gp96 or an active fragment or variant thereof may be formulated into any dosage form known in the medical field, eg, a tablet , pills, suspensions, emulsions, solutions, gels, capsules, powders, granules, elixirs, lozenges, suppositories, injections (including injections, lyophilized powders) and the like.
  • the polypeptides (or variants thereof), fusion proteins or pharmaceutical compositions of the present invention can be formulated as injectable solutions or lyophilized powders.
  • polypeptides (or variants thereof) or fusion proteins of the present invention may be present in pharmaceutical compositions in unit dosage form for ease of administration.
  • the polypeptide (or variant thereof), fusion protein or pharmaceutical composition of the present invention, or the C-terminal domain of gp96 or an active fragment or variant thereof may be administered by any suitable method known in the art, including Without limitation, oral, buccal, sublingual, ocular, topical, parenteral, rectal, intrathecal, intracytoplasmic reticulum, inguinal, intravesical, topical (eg, powder, ointment, or drops), or nasal route .
  • the preferred route/mode of administration is parenteral (eg, intravenous, subcutaneous, intraperitoneal, intramuscular).
  • the route and/or mode of administration will vary depending on the intended purpose.
  • the polypeptide (or variant thereof), fusion protein or pharmaceutical composition of the invention, or the C-terminal domain of said gp96 or an active fragment or variant thereof is administered by intravenous infusion or injection .
  • polypeptide (or its variant), fusion protein or pharmaceutical composition provided by the present invention, or the C-terminal domain of gp96 or its active fragment or its variant can be used alone or in combination, or with another pharmaceutical Active agents such as anti-inflammatory drugs or immunosuppressants are used in combination.
  • This additional pharmaceutically active agent may be administered before, concurrently with or after administration of the polypeptide (or variant thereof), fusion protein or pharmaceutical composition of the invention, or the C-terminal domain of said gp96 or an active fragment or variant thereof apply.
  • gp96 also known as Grp94, is a member of the heat shock protein 90 family located on the membrane of the endoplasmic reticulum of cells.
  • the gp96 protein consists of an N-terminal domain (N-terminal ATP-binding domain), an M-domain (charged intermediate domain), and a C-terminal domain (C-terminal homodimerization domain).
  • N-terminal ATP-binding domain N-terminal ATP-binding domain
  • M-domain charged intermediate domain
  • C-terminal homodimerization domain C-terminal homodimerization domain
  • amino acid sequence of gp96 protein when referring to the amino acid sequence of gp96 protein, it is described using the sequence shown in SEQ ID NO:7.
  • amino acid residues 578-713 of the gp96 protein refers to amino acid residues 578-713 of the polypeptide shown in SEQ ID NO:7.
  • amino acid sequence of gp96 mutations or variations can be naturally generated or artificially introduced without affecting its biological function. Therefore, in the present invention, the term "gp96" and similar expressions shall include all such sequences, including, for example, the sequence shown in SEQ ID NO: 7 and natural or artificial variants thereof.
  • sequence fragment of gp96 protein when describing the sequence fragment of gp96 protein, it includes not only the sequence fragment of SEQ ID NO:7, but also the corresponding sequence fragment in its natural or artificial variant.
  • amino acid residues 578-713 of gp96 protein includes, amino acid residues 578-713 of SEQ ID NO: 7, and corresponding fragments in variants (natural or artificial) thereof.
  • corresponding sequence fragment or “corresponding fragment” means that when the sequences are optimally aligned, ie when the sequences are aligned to obtain the highest percent identity, the sequences being compared are located in equivalent positions fragment.
  • isolated refers to artificially obtained from the natural state. If an "isolated” substance or component occurs in nature, it may be due to a change in its natural environment, or separation of the substance from its natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and the same polynucleotide or polypeptide with high purity isolated from this natural state is called isolated of.
  • isolated or isolated
  • the term "vector” refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted.
  • the vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector.
  • the vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements carried by it can be expressed in the host cell.
  • Vectors are well known to those skilled in the art and include, but are not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs) or P1 derived artificial chromosomes (PACs) ; Phage such as ⁇ phage or M13 phage and animal viruses.
  • YACs yeast artificial chromosomes
  • BACs bacterial artificial chromosomes
  • PACs P1 derived artificial chromosomes
  • Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (eg, herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses Polyoma vacuolar virus (eg SV40).
  • retroviruses including lentiviruses
  • adenoviruses eg, adeno-associated viruses
  • herpesviruses eg, herpes simplex virus
  • poxviruses baculoviruses
  • papillomaviruses papillomaviruses
  • Polyoma vacuolar virus eg SV40
  • a vector may contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and
  • the term "host cell” refers to a cell that can be used to introduce a vector, including, but not limited to, prokaryotic cells such as E. coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, etc., Insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
  • prokaryotic cells such as E. coli or Bacillus subtilis
  • fungal cells such as yeast cells or Aspergillus, etc.
  • Insect cells such as S2 Drosophila cells or Sf9
  • animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
  • stringent conditions for hybridization refer to conditions under which specific hybrids are formed but non-specific hybrids are not formed.
  • Typical stringent conditions include, for example, conditions under which the hybridization is performed at a potassium concentration of about 25 mM to about 50 mM and a magnesium concentration of about 1.0 mM to about 5.0 mM.
  • stringent conditions may refer to conditions under which hybridization is performed under Tris-HCl (pH 8.6), 25 mM KCl, and 1.5 mM MgCl 2 , but are not limited thereto. Those skilled in the art can easily select such conditions by changing the hybridization reaction, the salt concentration of the hybridization reaction solution, and the like.
  • identity is used to refer to the match of sequences between two polypeptides or between two nucleic acids.
  • a position in both sequences being compared is occupied by the same base or amino acid monomer subunit (e.g., a position in each of two DNA molecules is occupied by an adenine, or both A position in each of the polypeptides is occupied by a lysine)
  • the molecules are identical at that position.
  • the "percent identity” between two sequences is a function of the number of matched positions shared by the two sequences divided by the number of positions compared x 100. For example, two sequences are 60% identical if 6 out of 10 positions match.
  • the DNA sequences CTGACT and CAGGTT share 50% identity (matching at 3 positions out of a total of 6).
  • comparisons are made when two sequences are aligned for maximum identity.
  • Such alignment can be accomplished using, for example, the method of Needleman et al. (1970) J. Mol. Biol. 48:443-453, which can be conveniently performed by a computer program such as the Align program (DNAstar, Inc.).
  • Align program DNAstar, Inc.
  • Appl Biosci., 4:11-17 (1988)) integrated into the ALIGN program (version 2.0) can also be used, using the PAM120 weight residue table , a gap length penalty of 12, and a gap penalty of 4 to determine the percent identity between two amino acid sequences.
  • the algorithm of Needleman and Wunsch (J MoI Biol. 48:444-453 (1970)) in the GAP program integrated into the GCG software package (available at www.gcg.com), using the Blossum 62 matrix or PAM250 matrix with gap weights of 16, 14, 12, 10, 8, 6, or 4 and length weights of 1, 2, 3, 4, 5, or 6 to determine percent identity between two amino acid sequences .
  • conservative substitutions means amino acid substitutions that do not adversely affect or alter the intended properties of the protein/polypeptide comprising the amino acid sequence.
  • conservative substitutions can be introduced by standard techniques known in the art such as site-directed mutagenesis and PCR-mediated mutagenesis.
  • Conservative amino acid substitutions include substitutions of amino acid residues with amino acid residues that have similar side chains, e.g., that are physically or functionally similar to the corresponding amino acid residues (e.g., have similar size, shape, charge, chemical properties, including the ability to form covalent bonds or hydrogen bonds, etc.) Families of amino acid residues with similar side chains have been defined in the art.
  • These families include those with basic side chains (eg, lysine, arginine, and histidine), acidic side chains (eg, aspartic acid, glutamic acid), uncharged polar side chains (eg, glycine) , asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g.
  • alanine, valine, leucine, isoleucine amino acid, proline, phenylalanine, methionine), beta branched side chains (eg, threonine, valine, isoleucine), and aromatic side chains (eg, tyrosine, phenylalanine, tryptophan, histidine). Therefore, it is preferred to replace the corresponding amino acid residue with another amino acid residue from the same side chain family.
  • Methods for identifying conservative substitutions of amino acids are well known in the art (see, eg, Brummell et al., Biochem. 32:1180-1187 (1993); Kobayashi et al. Protein Eng. 12(10):879-884 (1999) and Burks et al. Proc. Natl Acad. Set USA 94:412-417 (1997), which is incorporated herein by reference).
  • amino acids are generally represented by one-letter and three-letter abbreviations well known in the art.
  • alanine can be represented by A or Ala.
  • the term "subject” includes, but is not limited to, various animals, particularly mammals such as humans.
  • the subject eg, human
  • the term "pharmaceutically acceptable carrier and/or excipient” refers to a carrier and/or excipient that is pharmacologically and/or physiologically compatible with the subject and the active ingredient , which are well known in the art (see, e.g., Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and include, but are not limited to: pH adjusters, surfactants, ionic strength enhancers, Agents for maintaining osmotic pressure, agents for delaying absorption, diluents, adjuvants, preservatives, stabilizers, etc.
  • pH adjusting agents include, but are not limited to, phosphate buffers.
  • Surfactants include, but are not limited to, cationic, anionic or nonionic surfactants, such as Tween-80.
  • Ionic strength enhancers include, but are not limited to, sodium chloride.
  • Agents for maintaining osmotic pressure include, but are not limited to, sugars, NaCl, and the like.
  • Agents that delay absorption include, but are not limited to, monostearate salts and gelatin.
  • Diluents include, but are not limited to, water, aqueous buffers (eg, buffered saline), alcohols and polyols (eg, glycerol), and the like.
  • Adjuvants include, but are not limited to, aluminum adjuvants (eg, aluminum hydroxide), Freund's adjuvants (eg, complete Freund's adjuvant), and the like.
  • Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, parabens, chlorobutanol, phenol, sorbic acid, and the like.
  • Stabilizers have the meaning generally understood by those skilled in the art, which are capable of stabilizing the desired activity of the active ingredient in the drug (such as the inhibitory activity on ubiquitination of PSD-95), including but not limited to sodium glutamate, gelatin, SPGA, Sugars (such as sorbitol, mannitol, starch, sucrose, lactose, dextran, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dried whey, albumin or casein) or their degradation Products (such as lactalbumin hydrolyzate), etc.
  • treating refers to treating or curing a disease (eg, an autoimmune disease), delaying the onset of one or more symptoms of the disease, and/or delaying the progression of the disease.
  • a disease eg, an autoimmune disease
  • a therapeutically effective amount refers to an amount effective to achieve the intended purpose.
  • a therapeutically effective amount can be an amount effective or sufficient to treat or cure a disease (eg, an autoimmune disease), delay the onset of one or more symptoms of the disease, and/or delay the progression of the disease.
  • a disease eg, an autoimmune disease
  • Such effective amounts can be readily determined by one skilled in the art or by a physician, and can be related to the intended purpose, the general health of the subject, age, sex, weight, severity of the disease to be treated, complications, mode of administration, etc. . Determination of such effective amounts is well within the purview of those skilled in the art.
  • polypeptides of the present invention include, but are not limited to, one or more selected from the group consisting of:
  • an autoimmune disease eg, systemic lupus erythematosus, type 1 diabetes, rheumatoid arthritis, ankylosing spondylitis
  • an autoimmune disease eg, systemic lupus erythematosus, type 1 diabetes, rheumatoid arthritis, ankylosing spondylitis
  • the polypeptides (or variants thereof) of the present invention and fusion proteins containing the polypeptides (or variants thereof) have significant advantageous aspects.
  • the polypeptides (or variants thereof) and fusion proteins of the present invention can specifically induce the activation of regulatory T cells, but not the activation of effector T cells and B cells, thereby avoiding that the full-length gp96 protein may aggravate autoimmune diseases potential risk of progression.
  • the ability of the polypeptide (or its variant) and fusion protein of the present invention to induce the activation of regulatory T cells is obviously better than that of the full-length gp96 protein, and has better immunomodulatory activity. Therefore, the polypeptides (or variants thereof) and fusion proteins of the present invention are particularly suitable for the treatment of autoimmune diseases and have great clinical value.
  • Figure 1 shows the percentage of regulatory T cells (Tregs) in mice immunized with 100 ⁇ g of different gp96 protein fragments (% CD3 + CD4 + CD25 + Foxp3 + Tregs/CD3 + CD4 + T cells). *, P ⁇ 0.05; **, P ⁇ 0.01
  • FIG. 2 shows the percentage of regulatory T cells (Tregs) in mice immunized with 300 ⁇ g of different gp96 protein fragments (% CD3 + CD4 + CD25 + Foxp3 + Tregs/CD3 + CD4 + T cells). *,P ⁇ 0.05;***,P ⁇ 0.001
  • FIG. 3 shows the percentage of regulatory T cells (Tregs) in mice immunized with 500 ⁇ g of different gp96 protein fragments (% CD3 + CD4 + CD25 + Foxp3 + Tregs/CD3 + CD4 + T cells). *,P ⁇ 0.05;***,P ⁇ 0.001
  • Figure 4 shows the percentage of regulatory T cells (Tregs) (% CD3 + CD4 + CD25 + Foxp3 + Tregs/CD3 + CD4 + T cells) in mice immunized with 300 ⁇ g of different polypeptide fragments and full-length gp96. **, peptides vs gp96 group, P ⁇ 0.01
  • Figure 5 shows the percentage of activated CD4 + T cells (INF ⁇ + CD4 + T/CD4 + T) after immunizing mice with 30 ⁇ g or 300 ⁇ g of different polypeptide fragments and full-length gp96 in combination with ovalbumin (NP-OVA). **, P ⁇ 0.01; ***, P ⁇ 0.001
  • Figure 6 shows the percentage of activated CD8 + T cells (INF ⁇ + CD8 + T/CD8 + T) after immunizing mice with 30 ⁇ g or 300 ⁇ g of different polypeptide fragments and full-length gp96 in combination with ovalbumin (NP-OVA). **, P ⁇ 0.01; ***, P ⁇ 0.001
  • Figure 7 shows the level of anti-OVA antibody IgG in mouse serum after immunizing mice with 300 ⁇ g of different polypeptide fragments and full-length gp96. **, P ⁇ 0.01
  • Figure 8 shows the levels of anti-dsDNA antibodies in mouse serum after immunization of Lyn(-/-) mice with 100 ⁇ g, 300 ⁇ g or 500 ⁇ g of different polypeptide fragments and full-length gp96.
  • the gp96 group compared with the PBS group P ⁇ 0.001 (“***")
  • the peptide group compared with the gp96 group P ⁇ 0.05 (“*")
  • Figure 9 shows the protein levels in mouse urine after immunizing Lyn(-/-) mice with 100 ⁇ g, 300 ⁇ g or 500 ⁇ g of different polypeptide fragments and full-length gp96.
  • the gp96 group compared with the PBS group P ⁇ 0.001 (“***")
  • the peptide group compared with the gp96 group P ⁇ 0.05 (“*")
  • Figure 10 shows the prevalence of T1D in a NOD mouse prevention model after immunization with 100 ⁇ g, 300 ⁇ g or 500 ⁇ g of different polypeptide fragments and full-length gp96.
  • Figure 11 shows the blood glucose levels in NOD mouse prophylaxis model after immunization with 100 ⁇ g, 300 ⁇ g or 500 ⁇ g of different polypeptide fragments and full-length gp96. At the same dose, the peptide group compared with the gp96 group, P ⁇ 0.05 ("*")
  • Figure 12 shows the percentage of activated CD8 + T cells (INF ⁇ + CD8 + T/CD8 + T) in the spleen cells of NOD mice prophylaxis model after immunization with 100 ⁇ g, 300 ⁇ g or 500 ⁇ g of different polypeptide fragments and full-length gp96. At the same dose, the peptide group compared with the gp96 group, P ⁇ 0.05 ("*")
  • Figure 13 shows the blood glucose level in NOD mouse treatment model after immunization with 300 ⁇ g of different polypeptide fragments and full-length gp96. At the same dose, the peptide group compared with the gp96 group, P ⁇ 0.05 ("*")
  • Figure 14 shows the blood glucose levels in the NOD mouse treatment model after immunization with 300 ⁇ g of Peptide 1 and its amino acid deletion and substitution mutations.
  • Figure 15 shows the blood glucose levels in the NOD mouse treatment model after immunization with 300 ⁇ g of Peptide 15 and its amino acid deletion and substitution mutations.
  • Figure 16 shows the detection results of rheumatoid inflammatory index in the induced mouse joint inflammation model after immunization with different polypeptide fragments and full-length gp96.
  • Fig. 17 shows the detection results of peripheral joint inflammation index in the induced mouse ankylosing spondylitis model after immunization with different polypeptide fragments and full-length gp96.
  • Table 1 Information on sequences referred to in this application is described in the table below.
  • the female Lyn(-/-) knockout mouse model of systemic lupus erythematosus can be found in the following literature: Hibbs ML, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell (1995) 83(2) :301–11; Yu CC, Yen TS, Lowell CA, DeFranco AL. Lupus-like kidney disease in mice deficient in the Src family tyrosine kinases Lyn and Fyn. Curr Biol. 2001 Jan 9; 11(1): 34-8.
  • Sf9 cells were purchased from Invitrogen, catalog number: 11496-015;
  • the pFastBac TM 1 plasmid was purchased from Invitrogen, catalog number: 10359-016;
  • DH10Bac TM competent cells were purchased from Invitrogen Company, product catalog number: 10361-012;
  • Insect-XPRESSTM Protein-free Insect Cells medium with L-Glutamine was purchased from LONZA Company, product catalog number: 12-730Q;
  • Ultrafiltration tubes were purchased from Merck Millipore Company, catalog number: UFC905096;
  • the ELISA kit was purchased from eBioscience, product catalog number: BMS614INST;
  • Ni affinity chromatography prepacked column was purchased from Aladdin Company, product catalog number: N5289-01;
  • Superdex 200 10/300 GL molecular sieve column was purchased from GE, catalog number: 17517501;
  • Escherichia coli DH10Bac competent cells were purchased from Beijing Yuanpinghao Biotechnology Co., Ltd., catalog number: CL108-01.
  • Example 1 Preparation of full-length gp96 or different gp96 truncations
  • the recombinant plasmid pFastBac1-DNAs containing the coding sequence of full-length gp96 or different gp96 truncations was synthesized by GenScript Biotechnology Co., Ltd.
  • the amino acid sequences and coding nucleic acid sequences of the involved full-length gp96 or different gp96 truncations are shown in Table 1.
  • the recombinant plasmids were transformed into DH10Bac TM competent cells, respectively, and recombinant bacmid DNA was obtained through recombination screening. All gp96 protein fragments and polypeptides carry a 6xHis tag at the C-terminus, and the DNA sequence of the tag is CACCACCACCATCACCAC (SEQ ID NO: 63).
  • the sample solution was loaded on the Ni affinity chromatography column.
  • the sample flow rate was controlled at 1 ml/min, then washed with imidazole-free Tris-HCl buffer, eluted with imidazole-containing Tris-HCl buffer, and the eluate was harvested.
  • the eluate is concentrated by ultrafiltration with an ultrafiltration tube with a molecular weight cut-off of 10KD to obtain a concentrated solution of about 1 ml.
  • the concentrate contained the recombinant gp96 C-terminal protein.
  • Example 2 Evaluation of mouse regulatory T cell activity induced by full-length gp96 or different gp96 truncations
  • This example examines gp96 full-length protein (SEQ ID NO: 7), truncated body gp96-N (SEQ ID NO: 8), gp96-M (SEQ ID NO: 10), gp96-N+M (SEQ ID NO: 10) : 9), gp96-C (SEQ ID NO: 11) and gp96-C+M (SEQ ID NO: 12) induced mice to produce regulatory T cells. Add a 6xHis tag to the C-terminus of each of the above proteins or polypeptides.
  • gp96-N corresponds to the amino acid residues 550-578 of the full-length protein
  • gp96-M corresponds to the amino acid residues 578-713 of the full-length protein
  • gp96-C corresponds to the 713-th amino acid residues of the full-length protein Amino acid residue 803.
  • mice purchased from Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd. weighing 14-16 g were randomly divided into gp96 treatment group, gp96-N treatment group, gp96-M treatment group, and recombinant The gp96-N+M treatment group was recombined, the gp96-C treatment group, the gp96-C+M treatment group and the control group (5 mice in each group) were treated as follows:
  • gp96-N treatment group the mice grew to the 9th week of age, and the purified gp96-N solution prepared in Example 1 was subcutaneously injected into the abdomen, which was recorded as the first day of the experiment; after the eighth day of the experiment, the abdomen was injected subcutaneously again.
  • Each injection dose was 100 ⁇ g, 300 ⁇ g or 500 ⁇ g gp96-N/mouse.
  • gp96-M treatment group the mice grew to the 9th week of age, and the purified gp96-M solution prepared in Example 1 was subcutaneously injected into the abdomen, which was recorded as the first day of the experiment; after the eighth day of the experiment, the abdomen was injected subcutaneously again.
  • the dose of each injection is 100 ⁇ g, 300 ⁇ g or 500 ⁇ g gp96-M/only.
  • gp96-N+M treatment group the mice grew to the 9th week of age, and the purified gp96-N+M solution prepared in Example 1 was subcutaneously injected into the abdomen, which was recorded as the first day of the experiment; The purified gp96-N+M solution prepared in Example 1 was subcutaneously injected into the abdomen; on the 22nd day of the experiment, the purified gp96-N+M solution prepared in Example 1 was subcutaneously injected into the abdomen again. The dose of each injection is 100 ⁇ g, 300 ⁇ g or 500 ⁇ g gp96-N+M/only.
  • gp96-C treatment group the mice grew to the 9th week of age, and the purified gp96-C prepared in Example 1 was subcutaneously injected into the abdomen, which was recorded as the first day of the experiment; after the 8th day of the experiment, the purified gp96-C prepared in Example 1 was subcutaneously injected into the abdomen again. On the 22nd day of the experiment, the purified gp96-C solution prepared in Example 1 was subcutaneously injected into the abdomen again. The dose of each injection is 100 ⁇ g, 300 ⁇ g or 500 ⁇ g gp96-C / only.
  • gp96-C+M treatment group the mice grew to the 9th week of age, and the purified gp96-C+M prepared in Example 1 was subcutaneously injected into the abdomen, which was recorded as the first day of the experiment; after the 8th day of the experiment, the abdomen was subcutaneously injected again The purified gp96-C+M solution prepared in Example 1; on the 22nd day of the experiment, the purified gp96C-3 solution prepared in Example 1 was subcutaneously injected into the abdomen again. The dose of each injection is 100 ⁇ g, 300 ⁇ g or 500 ⁇ g gp96-C+M/only.
  • Full-length gp96 treatment group mice grew to the 9th week of age, and the purified gp96-C+M prepared in Example 1 was subcutaneously injected into the abdomen, which was recorded as the first day of the experiment; after the 8th day of the experiment, the abdomen was subcutaneously injected again Example 1.
  • the solution of purified gp96-C+M prepared; on the 22nd day of the experiment, the solution of full-length gp96 prepared in Example 1 was subcutaneously injected into the abdomen again.
  • the dose of each injection is 100 ⁇ g, 300 ⁇ g or 500 ⁇ g gp96/only.
  • Control group On the 1st day of the experiment, pH7.2, 0.01mol/L PBS buffer was subcutaneously injected into the abdomen, on the 8th day of the experiment, pH7.2, 0.01mol/L PBS buffer was subcutaneously injected into the abdomen; on the 22nd day of the experiment, the abdomen was injected again Subcutaneous injection of pH7.2, 0.01mol/L PBS buffer.
  • the dose of PBS for each injection was 100 ⁇ l/a, 300 ⁇ g or 500 ⁇ l/a.
  • mice On the 25th day, the mice were sacrificed, and the spleen of the mice was isolated to prepare mouse spleen lymphocytes.
  • the percentage of regulatory T cells (Tregs) in the mice was analyzed by flow cytometry (% CD3 + CD4 + CD25 + Foxp3 + Tregs/CD3 + CD4 + T cells). See Xinghui Li, et al. 2013. Induction of regulatory T cells by high-dose gp96 suppresses murine liver immune hyperactivation. PLoS One.8(7):e68997 for details on the isolation and detection methods of regulatory T cells.
  • Figure 1-3 shows the percentage of regulatory T cells (Tregs) in mice immunized with 100 ⁇ g, 300 ⁇ g and 500 ⁇ g of different gp96 protein fragments, respectively.
  • the results showed that the percentage of regulatory T cells in mice immunized with 100 ⁇ g, 300 ⁇ g or 500 ⁇ g gp96-C, gp96-C+M protein was significantly higher than that in the control group (PBS) or gp96-N, gp96-M, gp96-N+M
  • the immunization group P ⁇ 0.05 or P ⁇ 0.001
  • the levels of regulatory T cells in the gp96-C and gp96-C+M protein immunization groups were significantly higher than those in the full-length gp96 immunization group (P ⁇ 0.05), while gp96-N, gp96
  • Example 3 Preparation of different truncations based on the C-terminal domain of gp96 protein and evaluation of their induction of mouse regulatory T cell activity
  • the full-length C-terminal of gp96 has a total of 255 amino acid residues, which were truncated and divided into 17 different polypeptide fragments: Peptide 1-Peptide 17, and their amino acid sequences are shown in SEQ ID NOs: 30-46 respectively.
  • a 6xHis tag was added to the C-terminus of each of the above polypeptides, and the above 17 polypeptides were expressed and prepared by the method in Example 1, respectively.
  • mice Ninety-five six-week-old C57BL/6 mice weighing 14-16 g were randomly divided into 19 groups, with Peptide 1-Peptide 17 experimental group, PBS and gp96 control group, 5 mice in each group.
  • mice were grown to the age of 9 weeks, and the corresponding protein (polypeptide) or PBS was subcutaneously injected into the abdomen on the first day of the experiment, and the abdominal subcutaneous injection was performed again on the eighth day of the experiment.
  • the dose of each injection is 300 ⁇ g/only.
  • mice were sacrificed on the 25th day, and the mouse spleen was taken to separate and prepare mouse spleen lymphocytes. Flow cytometry was used to analyze the percentage of regulatory T cells in mice immunized with different recombinant polypeptide fragments. The isolation and detection methods of regulatory T cells are as in Example 2.
  • the test results are shown in Figure 4.
  • the results show that the percentage of regulatory cells in mice treated with Peptide 1, Peptide 2, Peptide 3, Peptide 4, Peptide 8, Peptide 13, Peptide 14, and Peptide 15 was significantly higher than that in the control group (PBS) (P ⁇ 0.001), and all were higher than the full-length gp96 treatment group (P ⁇ 0.01).
  • the amino acid sequence contained in Peptide 15 is an essential sequence for activating regulatory T cells.
  • Example 4 Evaluation of mouse effector T cell activity induced by different truncations based on the C-terminal domain of gp96 protein
  • mice 110 six-week-old C57BL/6 mice weighing 14-16 g were randomly divided into 22 groups, with Peptide 1, Peptide 2, Peptide 3, Peptide 4, Peptide 8, Peptide 13, Peptide 14, Peptide 15 Long gp96 combined with ovalbumin (NP-OVA) (purchased from Beijing Biopac Biotechnology Co., Ltd., item number: T-5051-100*100mg) experimental group, NP-OVA alone or PBS control group (5 mice in each group). mouse).
  • NP-OVA ovalbumin
  • mice were grown to the age of 9 weeks.
  • the corresponding polypeptides or full-length gp96 combined with NP-OVA, or NP-OVA or PBS alone were injected subcutaneously in the abdomen.
  • the abdominal subcutaneous injection was performed again; day, subcutaneous injection in the abdomen again.
  • the dose of each injection of polypeptide or full-length gp96 was 30 ⁇ g or 300 ⁇ g/mouse, and the dose of OVA protein was 20 ⁇ g/mouse.
  • mice were sacrificed on the 25th day, the spleen cells of the mice were isolated, and the percentage of activated CD4 + T cells and CD8 + T cells in the mice after immunization was analyzed by flow cytometry. See Xinghui Li, et al.2013 . Induction of regulatory T cells by high - dose gp96 suppresses murine liver immune hyperactivation. PLoS One.8(7): e68997.
  • the detection results of the percentage of activated CD4 + T cells and CD8 + T cells are shown in Figure 5 and Figure 6, respectively.
  • the percentages of activated CD4 + T cells and CD8 + T cells in the groups treated with peptide fragments of , Peptide 14 and Peptide 15 were not significantly different from those in the control group (PBS), while the activated CD4 cells in the 30 ⁇ g immunization dose of full-length gp96 group
  • the percentages of + T cells and CD8 + T cells were significantly higher than those in the control group (PBS) (P ⁇ 0.001) and the OVA immunized group (P ⁇ 0.01), and the activated CD4 + T cells and
  • the percentage of CD8 + T cells was significantly higher than that of the control group (PBS) (P ⁇ 0.01), which indicated that effector T cells were not activated by peptide fragment immunization, while full-length gp96 could significantly activate effector T cells.
  • the level of anti-OVA antibody IgG in the serum of mice immunized with 300 ⁇ g of different polypeptide fragments and full-length gp96 was further detected by ELISA.
  • ELISA For the detection method, please refer to Bettina Eide Holm, et al. 2015. Antibldies with specificity for native and denatured forms of ovalbumin differ in reactivity between enzyme-linked immunosorbent assays. APMIS. 123(2):136-45.
  • the test results are shown in Figure 7.
  • the results show that the serum anti-OVA antibody levels in mice treated with 300 ⁇ g immunized doses of Peptide 1, Peptide 2, Peptide 3, Peptide 4, Peptide 8, Peptide 13, Peptide 14, and Peptide 15 polypeptide fragments were compared with the control group.
  • Groups (PBS) were not significantly different and significantly lower than full-length gp96 immunized mice (all P ⁇ 0.05), suggesting that effector B cells were not activated by polypeptide fragment immunization.
  • Example 5 Application of different truncations based on the C-terminal domain of gp96 protein in the treatment of systemic lupus erythematosus
  • mice weighing 14-16g were randomly divided into Peptide 1, Peptide 2, Peptide 3, Peptide 4, Peptide 8, Peptide 13, Peptide 14, Peptide 15 polypeptides, full-length
  • the gp96 immunized group and the control group (PBS) (10 mice in each group) were treated as follows: the mice were grown to the 7th week, the 8th week, the 10th week, the 12th week, the 14th week, the At the age of 16 weeks, the purified recombinant polypeptide prepared in Example 1 and Example 3, full-length gp96 or PBS were subcutaneously injected into the abdomen of mice, and the dose of each injection per mouse was 100 ⁇ g, 300 ⁇ g or 500 ⁇ g.
  • mice When the mice grew to 20 weeks of age, 200 ⁇ l of blood was collected from the orbit. Incubate at room temperature for 30 min, centrifuge at 3000 rpm for 20 min, and take the supernatant.
  • the level of anti-double-stranded DNA antibodies in serum was determined by enzyme-linked immunosorbent assay (ELISA), and the steps were as follows:
  • HRP-labeled anti-mouse secondary antibody purchased from Zhongshan Jinqiao, 1:5000 dilution
  • 50 ⁇ l per well 50 ⁇ l per well. Incubate at 37°C for 60 minutes.
  • Urine protein detection kit was purchased from Nanjing Jiancheng Bioengineering Institute (Item No.: C035-2)
  • mice The urine protein detection results of mice are shown in Figure 9.
  • the results showed that the urinary protein levels of mice treated with Peptide 1, Peptide 2, Peptide 3, Peptide 4, Peptide 8, Peptide 13, Peptide 14, and Peptide 15 polypeptides were significantly lower than those in the control group (PBS) (P ⁇ 0.001), and also Significantly lower than the full-length gp96 treatment group (P ⁇ 0.05). This shows that the effect of polypeptide in the treatment of systemic lupus erythematosus is better than that of full-length gp96.
  • Example 6 Application of different truncations based on the C-terminal domain of gp96 protein in the prevention of type 1 diabetes
  • mice with a body weight of 14-16g were randomly divided into Peptide 1, Peptide 2, Peptide 3, Peptide 4, Peptide 8, Peptide 13, Peptide 14, Peptide 15 polypeptide, full-length gp96 immunization group and The control group (PBS) (10 mice in each group) were treated as follows: when the mice grew to the 7th, 8th, 10th, 12th, and 14th weeks of age, they were treated at The purified recombinant polypeptide prepared in Example 1 and Example 3, full-length gp96 or PBS were subcutaneously injected into the abdomen of mice, and the dose per injection per mouse was 100 ⁇ g, 300 ⁇ g or 500 ⁇ g, respectively.
  • mice From the 9th week of age in NOD mice, the blood glucose level of the mice was monitored, and 1 drop of tail vein blood was taken from the mice, and the blood glucose meter (Roche, Germany) was used to measure the blood glucose level. Performa) according to the instructions to measure the blood sugar level, and statistics the prevalence. Diabetes mellitus (T1D) was diagnosed with blood glucose value >13.3 mmol/L for more than 2 times.
  • mice immunized with Peptide 1, Peptide 2, Peptide 3, Peptide 4, Peptide 8, Peptide 13, Peptide 14, and Peptide 15 polypeptides is significantly lower than that of full-length mice.
  • gp96-immunized mice (P ⁇ 0.05 or P ⁇ 0.01), and control mice (PBS) all developed disease at 11-14 weeks of age.
  • mice were sacrificed at the age of 20 weeks, the spleen cells of the mice were isolated, and the percentage of activated CD8 + T cells in the mice after immunization was analyzed by flow cytometry. The detection results are shown in Figure 12. The results showed that the percentage of activated CD8 + T cells in mice treated with Peptide 1, Peptide 2, Peptide 3, Peptide 4, Peptide 8, Peptide 13, Peptide 14, and Peptide 15 polypeptide fragments was significantly lower than that in mice in the full-length gp96 group ( P ⁇ 0.05).
  • Example 7 Application of different truncations based on the C-terminal domain of gp96 protein in the treatment of type 1 diabetes
  • mice with a body weight of 14-16g were randomly divided into Peptide 1, Peptide 2, Peptide 3, Peptide 4, Peptide 8, Peptide 13, Peptide 14, Peptide 15 polypeptide, full-length gp96 immunization group and The control group (PBS) (10 mice in each group) were treated as follows: when the mice grew to the 14th, 15th, 17th, 19th and 21st weeks of age, they were treated at The purified polypeptide prepared in Example 1 and Example 3, full-length gp96 or PBS were subcutaneously injected into the abdomen of mice, and the dose per injection was 300 ⁇ g per mouse.
  • mice The blood glucose level of the mice was monitored from the first week after the last immunization and was detected once a week. Take 1 drop of mouse tail vein blood, use a blood glucose meter (Roche, Germany Performa) Determination of blood glucose levels according to the instructions.
  • the test results of blood glucose concentration in mice are shown in Figure 13.
  • the results showed that the blood glucose concentration of mice immunized with Peptide 1, Peptide 2, Peptide 3, Peptide 4, Peptide 8, Peptide 13, Peptide 14, and Peptide 15 polypeptides gradually decreased with time, and the final concentration was significantly lower than that of the control group ( PBS) (P ⁇ 0.001), and the blood glucose levels of mice in all polypeptide immunized groups were also significantly lower than those in full-length gp96 immunized groups (P ⁇ 0.05).
  • Example 8 Application of mutant polypeptide fragments in the treatment of type 1 diabetes
  • Peptide 1 and Peptide 15 polypeptides were randomly selected to mutate three amino acid sites into alanine (Ala), which were recorded as Peptide 1m-1 (SEQ ID NO:55), Peptide 1m-2 (SEQ ID NO:56) , Peptide 15m-1 (SEQ ID NO: 59), Peptide 15m-2 (SEQ ID NO: 60), and then the three amino acid sites in Peptide 1 and Peptide 15 were deleted and recorded as Peptide 1d-1 (SEQ ID NO: 60). NO:57), Peptide 1d-2 (SEQ ID NO:58), Peptide15d-1 (SEQ ID NO:61), Peptide15d-2 (SEQ ID NO:62).
  • mice with body weight of 14-16g were randomly divided into Peptide 1, Peptide 1m-1, Peptide 1m-2, Peptide 1d-1, Peptide 1d-2, Peptide 15, Peptide 15m-1, Peptide 15m-2, Peptide 15d-1, and Peptide 15d-2 polypeptide immunization groups (10 mice in each group) were treated as follows: mice were grown to the 14th week, 15th week, 17th week, and 19th week. At the age of 21 weeks, the mice were subcutaneously injected with the polypeptide prepared according to the method in Example 1 in the abdomen of the mice, and the dose per injection was 300 ⁇ g per mouse.
  • mice The blood glucose level of the mice was monitored from the first week after the last immunization and was detected once a week. Take 1 drop of mouse tail vein blood, use a blood glucose meter (Roche, Germany Performa) Determination of blood glucose values according to the instructions.
  • Figure 15 shows the test results of blood glucose concentration in mice immunized with Peptide 15 amino acid deletion and substitution mutant polypeptides. The results show that the blood glucose concentration of mice immunized with mutated polypeptides is not significantly different from that of unmutated polypeptides, indicating that some mutant polypeptides and unmutated polypeptides have the same therapeutic function.
  • Example 9 Application of different truncations based on the C-terminal domain of gp96 protein in the treatment of induced murine joint inflammation
  • mice 310 six-week-old female DBA/1 mice (Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd.) weighing 14-16 g were randomly divided into Peptide 1, Peptide 2, Peptide 3, Peptide 4, Peptide 8, Peptide 13, Peptide 14, Peptide 15 polypeptide, full-length gp96 immunization group, control group (PBS) and model group (10 mice in each group), except 10 normal control groups, the remaining 300 mice were subjected to CIA modeling.
  • PBS control group
  • model group 10 mice in each group
  • mice were grown to the 10th week, the 11th week, and the 13th week, and the recombinant polypeptides prepared in Example 1 and Example 3 were subcutaneously injected into the abdomen of the mice. , full-length gp96 or PBS, each injection dose per mouse is 100 ⁇ g, 300 ⁇ g or 500 ⁇ g.
  • mice were given joint inflammation index scores on the 0th, 5th, 10th, 15th, 20th, 25th, and 30th days after administration, scoring standard: 0 points: no obvious joint redness and swelling; 1 point: ankle joint or mild redness and swelling of the toe joint; 2 points: mild redness and swelling from the toe joint to the ankle joint; 3 points: moderate redness and swelling from the toe joint to the ankle joint; 4 points: severe redness and swelling from the ankle joint to the entire sole of the foot, each The maximum score for mice is 16 points.
  • Paw thickness On the 0th, 5th, 10th, 15th, 20th, 25th, and 30th days after administration, the swollen paws were given to measure the thickness of the swelling, and the most swollen part was measured with a vernier caliper, and the unit was mm.
  • mice immunized with Peptide 1, Peptide 2, Peptide 3, Peptide 4, Peptide 8, Peptide 13, Peptide 14, and Peptide 15 polypeptides was significantly lower than that of the model group (P ⁇ 0.001), but also lower than the full-length gp96 treatment group (P ⁇ 0.05).
  • Similar results were obtained in mice treated with rheumatoid injections at doses of 100 ⁇ g or 500 ⁇ g. The above results show that immunizing mice with polypeptide can effectively treat the induced joint inflammation in mice, and its therapeutic effect is better than that of full-length gp96.
  • Example 10 Application of different truncations based on the C-terminal domain of gp96 protein in the treatment of induced ankylosing spondylitis
  • mice 310 six-month-old female BALB/c mice were randomly divided into Peptide 1, Peptide 2, Peptide 3, Peptide 4, Peptide 8, Peptide 13, Peptide 14, Peptide 15 polypeptide, full-length gp96 immunization group, control group (PBS). ) and model group (10 mice in each group), except the control group, the remaining 300 mice were induced by proteoglycan (PG) to induce ankylosing spondylitis in mice. 100 ⁇ g of cartilage proteoglycan (purchased from Sigma, Cat. No.: P5864) and 1 gg of DDA adjuvant (purchased from Avanti, Cat. abdominal cavity.
  • PG proteoglycan
  • Example 3 On the 8th day after the three immunizations, the following treatments were carried out: the recombinant polypeptides prepared in Example 1 and Example 3, full-length gp96 or PBS were subcutaneously injected into the abdomen of the mice every week, and the dose of each injection was 100 ⁇ g per mouse. , 300 ⁇ g or 500 ⁇ g.
  • Peripheral Arthritis Index detection After the third model immunization, peripheral arthritis was recorded every week for 7 consecutive weeks. Peripheral Arthritis Index scoring criteria: 0 points for absence of any inflammatory swelling, 1 point for swelling of one toe, 2 points for more than one toe involvement, 3 points for toe stiffness and loss of joint function, and 4 points for ankle swelling and stiffness , the limbs of the model mice were scored, and the total score was between 0-16.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)

Abstract

涉及疾病治疗领域。具体而言，提供了用于治疗自身免疫性疾病(例如系统性红斑狼疮、1型糖尿病、类风湿性关节炎、强直性脊柱炎)的多肽或其变体，包含此类多肽或其变体的融合蛋白，以及此类多肽或其变体和融合蛋白的医药用途。还涉及可用于治疗自身免疫性疾病(例如系统性红斑狼疮、1型糖尿病、类风湿性关节炎、强直性脊柱炎)或减轻自身免疫性疾病的一种或多种症状的药物组合物，其包含多肽或其变体或融合蛋白。

Description

用于治疗自身免疫性疾病的多肽 技术领域
本发明涉及疾病治疗领域。具体而言，本发明提供了用于治疗自身免疫性疾病(例如系统性红斑狼疮、1型糖尿病、类风湿性关节炎、强直性脊柱炎)的多肽或其变体，包含此类多肽或其变体的融合蛋白，以及此类多肽或其变体和融合蛋白的医药用途。本发明还涉及可用于治疗自身免疫性疾病(例如系统性红斑狼疮、1型糖尿病、类风湿性关节炎、强直性脊柱炎)或减轻自身免疫性疾病的一种或多种症状的药物组合物，其包含本发明的多肽或其变体或融合蛋白。
背景技术
自身免疫性疾病是由免疫系统自我耐受性受损或丧失而引起器官和组织损伤的一系列疾病。包括如系统性红斑狼疮(SLE)、1型糖尿病、类风湿性关节炎(RA)、强直性脊柱炎(AS)等。自身免疫疾病的患者免疫功能异常活化，攻击机体正常组织和器官，可累及全身多个系统发生疾病。
系统性红斑狼疮，英文systemic lupus erythematosus，简称SLE。系统性红斑狼疮属于自身免疫类疾病，常发生于20-40岁女性。本病病因至今尚未明确，大量研究显示遗传、内分泌、感染、免疫异常和一些环境因素与本病的发病可能有关。在遗传因素、环境因素、雌激素水平等各种因素相互作用下，患者T淋巴细胞减少、抑制性T细胞功能降低、B细胞过度增生，产生大量的自身抗体，并与体内相应的自身抗原结合形成相应的免疫复合物，沉积在皮肤、关节、小血管、肾小球等部位，引起急慢性炎症及组织坏死(如狼疮肾炎)，或抗体直接与组织细胞抗原作用，引起细胞破坏(如红细胞、淋巴细胞及血小板壁的特异性抗原与相应的自身抗体结合，分别引起溶血性贫血、淋巴细胞减少症和血小板减少症)，从而导致机体的多系统损害。
SLE的诊断主要依靠临床表现、实验室检查、组织病理学和影像学检查。1997年美国风湿病协会(ACR)修订的SLE分类标准中，明确将血液学异常、免疫学异常和自身抗体阳性等实验室检查列入了诊断标准。由于系统性红斑狼疮患者常存在血液系统异常和肾脏损伤等，血常规检查可有贫血、白细胞计数减少、血小板降低等症状；尿液分析可显示蛋白尿、血尿、细胞和颗粒管型。目前临床开展的系统性红斑狼 疮相关自身抗体常规检测项目主要有抗核抗体(ANA)、抗双链脱氧核糖核酸抗体(抗dsDNA抗体)、抗可溶性抗原抗体(抗ENA抗体)(包括抗Sm、抗U1RNP、抗SSA/Ro、抗SSB/La、抗rRNP、抗Scl-70和抗Jo-1等)、抗核小体抗体和抗磷脂抗体等。ACR修订的SLE分类标准中，免疫学异常和自身抗体阳性包括：抗Sm抗体、抗dsDNA抗体、抗磷脂抗体和ANA阳性。
1型糖尿病，英文type 1 diabetes mellitus，简称T1DM。T1DM是一种自身免疫性疾病，是由胰岛中的β细胞被免疫系统破坏引起的，T1DM可以在任何年龄发生，但通常最常见于青春期，并在青春期左右开始发作。研究表明遗传因素和环境因素在T1DM发病中都起作用，但尚不清楚T1DM的确切病因。目前T1MD的主要治疗方式依然是终身注射胰岛素控制血糖。
类风湿性关节炎，英文rheumatoid arthritis，简称RA。RA的特征为导致促炎细胞因子如肿瘤坏死因子α(TNF)白细胞介素1(IL-1)的过量产生的免疫系统的不平衡和抗炎细胞因子例如IL-10、IL-11的缺乏。RA通过滑膜发炎表征，滑膜炎进展为软骨破坏、骨侵蚀和随后的关节变形。RA的原发症状为是关节发炎、肿胀、移动困难和疼。在RA的后期，发炎细胞产生的酶会消化骨骼和软骨。长期的损伤导致关节的慢性疼痛、机能丧失、变形和甚至寿命变短。尽管近几年抗TNF治疗在治疗RA中已取得了不错的进展，但其只能用于部分患者，至少三分之一的RA患者不产生反应。因此成功的治疗关节炎仍然是一个未得到解决的医学需要。
强直性脊柱炎，英文ankylosing spondylitis，简称AS，是一种慢性、进行性、中轴关节和外周关节受累的慢性炎症性疾病。其主要影响骨盆的骶髂关节、脊柱关节和椎旁组织。主要症状为下腰痛、脊椎僵硬及运动范围受限。该疾病一般先侵犯骶髂关节，并重点累及脊柱，最终导致脊柱骨性强直，并可伴有心脏、眼部、肺部、等脏器不同层度的损害。
自身免疫性疾病具有很强的异质性，不论采用中医还是西医治疗绝大多数患者均不可能根治，只能通过药物缓解病情，长期服药会带来明显的毒副作用，给患者和家属带来巨大的经济和精神负担，因此开发新的治疗自身免疫性疾病方案和药物具有重要的社会和经济意义。
发明内容
热休克蛋白(Heat shock protein，HSP)是一类在生物进化中高度保守且广泛存在于原核及真核生物中的蛋白质。HSP根据同源程度及分子量大小可分为HSP110、HSP90、HSP70、HSP60、HSP40、小分子HSP及泛素等多个亚家族。人类热休克蛋白90家族(HSP90)包括HSP90α,HSP90β,gp96(grp94)和Trap-1四个成员。gp96(GRP94)为内质网HSP90家族的代表，与细胞质HSP90高度同源，主要生物学功能有：分子伴侣，参与新合成蛋白的折叠与组装；与细胞内的其他肽类蛋白质尤其是变性蛋白的结合，参与细胞的抗损伤、修复和热耐受过程；参与蛋白质水解过程；结合抗原肽，加工提呈肿瘤抗原及维持细胞内环境稳定等作用；对细胞的生长、发育、分化及死亡具有一定的调节作用。
已有研究报道，全长gp96虽然可以活化调节性T细胞(Treg)，然而其还具有强大的活化效应CD4 +T、CD8 +T细胞、B细胞等功能，不能特异性单独靶向调节性T细胞，因此全长gp96在治疗自身免疫性疾病中有可能活化免疫系统，导致治疗效果不佳，甚至有可能加重自身免疫疾病。
本申请的发明人经过大量的研究后出人意料地发现，全长gp96的特定多肽片段具有特异性单独靶向调节性T细胞、且不靶向效应T细胞及B细胞的活性，从而特别适用于自身免疫性疾病的治疗，具有重要临床应用价值。
分离的多肽或其变体
在一个方面，本发明提供了一种分离的多肽或其变体，其中，所述多肽由gp96蛋白的至少136个连续氨基酸残基组成，且包含：gp96蛋白的第578-713位氨基酸残基；
其中，所述变体与其所源自的多肽相异仅在于1个或几个(例如，1个、2个、3个、4个或5个)氨基酸残基的置换、缺失或添加，且保留了其所源自的多肽的生物学功能。
在本文中，本发明的多肽或其变体的生物学功能包括但不限于，诱导调节性T细胞活化，不诱导或基本不诱导效应T细胞和B细胞活化，治疗自身免疫性疾病或缓解自身免疫性疾病的一种或多种症状，降低抗双链DNA抗体的水平，降低尿蛋白的水平，和/或降低血糖。
本领域技术人员已知，在mRNA的翻译过程中，由于起始密码子的作用，所产生 的多肽链第一位经常为起始密码子编码的氨基酸(例如，甲硫氨酸(M))。因此，本发明的多肽或其变体不仅囊括在其N末端不包含起始密码子编码的氨基酸(例如，甲硫氨酸)的氨基酸序列，也囊括在其N末端包含起始密码子编码的氨基酸(例如，甲硫氨酸)的氨基酸序列。
在某些实施方案中，所述gp96蛋白为人源。在某些实施方案中，所述gp96蛋白具有如SEQ ID NO:7所示的氨基酸序列。
在某些实施方案中，本发明的分离的多肽由gp96蛋白的不多于254个的连续氨基酸残基组成，例如，由不多于250个，240个，230个，226个，224个，220个，210个，200个，196个，194个，190个，180个，170个，166个，164个，160个，150个，140个或136个的连续氨基酸残基组成。
在某些实施方案中，所述变体与其所源自的多肽相异仅在于1个或几个(例如，1个、2个、3个、4个或5个)氨基酸残基的置换、缺失或添加，所述置换是保守置换。
在某些实施方案中，所述变体与其所源自的多肽相异仅在于1个、2个或3个氨基酸残基的置换、缺失或添加。在某些实施方案中，所述置换包括将所述氨基酸残基替换为丙氨酸(A)。
在某些实施方案中，本发明的多肽包含：gp96蛋白的第578-713位氨基酸残基、第578-743位氨基酸残基、第578-773位氨基酸残基、第578-803位氨基酸残基、第550-713位氨基酸残基、第550-743位氨基酸残基、第550-773位氨基酸残基或第550-803位氨基酸残基。
在某些实施方案中，所述分离的多肽包含选自下列的氨基酸序列，或由其组成：SEQ ID NOs:30、31、32、33、37、42、43、44。此处所示序列在其N端包含起始密码子编码的甲硫氨酸。本领域技术人员理解，所述分离的多肽也可以包含在其N端不包含起始密码子编码的甲硫氨酸的上述氨基酸序列，或由其组成。
在某些实施方案中，所述变体包含选自下列的氨基酸序列，或由其组成：SEQ ID NOs:55-62。此处所示序列在其N端包含起始密码子编码的甲硫氨酸。本领域技术人员理解，所述变体也可以包含在其N端不包含起始密码子编码的甲硫氨酸的上述氨基酸序列，或由其组成。
融合蛋白
在另一方面，本发明提供了一种融合蛋白，其包含本发明的分离的多肽(或其变体)和另外的多肽。
在某些实施方案中，所述另外的多肽选自蛋白标签、靶向部分或其任意组合。
在本文中，蛋白标签是本领域熟知的，其实例包括但不限于His、Flag、GST、MBP、HA、Myc、GFP或生物素，并且本领域技术人员已知如何根据期望目的(例如，纯化、检测或示踪)选择合适的蛋白标签。
在本文中，术语“靶向部分”是指，能够将本发明的多肽(或其变体)引导至所期望的位置的结构域，所述期望的位置可以为特定的组织、特定的细胞、甚至特定的细胞内位置(例如细胞核、核糖体、内质网、溶酶体或过氧化物酶体)。本领域技术人员已知如何通过期望位置的特性设计相应的靶向结构域。在某些实施方案中，所述靶向部分包括配体、受体或抗体或其结合结构域。
在某些实施方案中，所述另外的多肽任选地通过接头连接至本发明的多肽(或其变体)的N端或C端。在某些实施方案中，所述接头为包含一个或多个(例如，1个，2个，3个，4个或5个)氨基酸(如，Gly或Ser)的序列。
多肽及融合蛋白的制备
本发明的多肽或其变体或融合蛋白不受其产生方式的限定，例如，其可以通过基因工程方法(重组技术)产生，也可以通过化学合成方法产生。
在另一方面，本发明提供了一种分离的核酸分子，其包含编码本发明的多肽或其变体或融合蛋白的核苷酸序列。
在某些实施方案中，所述分离的核酸分子包含选自下列的核苷酸序列：(i)SEQ ID NOs:13-16、20、25-27、47-54任一项所示的序列；(ii)与(i)所述序列相比具有至少70％、至少75％、至少80％、至少85％、至少90％、至少95％、至少99％的序列同一性的序列；(iii)在严格条件下与(i)或(ii)中所述的序列杂交的序列；或(iv)(i)或(ii)中所述的序列的互补序列。
在另一方面，本发明还提供了一种载体，其包含如上所述的分离的核酸分子。本发明的载体可以是克隆载体，也可以是表达载体。在某些实施方案中，本发明的载体是例如质粒，粘粒，噬菌体，柯斯质粒等等。
在另一方面，本发明还提供了包含本发明的分离的核酸分子或载体的宿主细胞。此类宿主细胞包括但不限于，原核细胞例如大肠杆菌细胞，以及真核细胞例如酵母细 胞，昆虫细胞(例如Sf9细胞)，植物细胞和动物细胞(如哺乳动物细胞，例如小鼠细胞、人细胞等)。
在另一方面，本发明还提供了制备本发明的多肽或其变体或融合蛋白的方法，其包括，在允许所述多肽或其变体或融合蛋白表达的条件下，培养本发明的宿主细胞，和从培养的宿主细胞培养物中回收所述多肽或其变体或融合蛋白。
药物组合物
在另一方面，本发明提供了一种药物组合物，其包含本发明的分离的多肽(或其变体)、融合蛋白、分离的核酸分子、载体或宿主细胞，以及药学上可接受的载体和/或赋形剂。
在某些实施方案中，所述药物组合物包含本发明的分离的多肽(或其变体)或融合蛋白中的一种或多种。
在某些实施方案中，所述药物组合物任选地还包含另外的药学活性剂，例如具有治疗自身免疫性疾病活性的药物。在某些实施方案中，所述另外的药学活性剂选自抗炎药物或免疫抑制剂，例如非甾体抗炎药、甾体抗炎药、致炎性细胞因子的抗体或拮抗剂、抗炎细胞因子等。
治疗应用
本申请的发明人首次发现，gp96的C末端结构域或其活性片段能够特异性活化调节性T细胞，而不活化效应T细胞及B细胞的活性，从而特别适用于自身免疫性疾病的治疗。
因此，在另一方面，本发明还涉及gp96的C末端结构域(即，C末端同源二聚结构域)或其活性片段或其变体、或本发明的分离的多肽(或其变体)、融合蛋白、分离的核酸分子、载体、宿主细胞或药物组合物用于在受试者中预防和/或治疗自身免疫性疾病或缓解自身免疫性疾病的一种或多种症状、或降低抗双链DNA抗体的水平、或降低尿蛋白的水平、或降低血糖的用途，或者在制备药物中的用途，所述药物用于在受试者中预防和/或治疗自身免疫性疾病或缓解自身免疫性疾病的一种或多种症状、或降低抗双链DNA抗体的水平、或降低尿蛋白的水平、或降低血糖。
在某些实施方案中，所述C末端结构域由gp96蛋白的第550-803位氨基酸残基组成。在某些实施方案中，所述C末端结构域具有如SEQ ID NO:30所示的序列。
在某些实施方案中，所述gp96的C末端结构域的活性片段或其变体选自本发明 的分离的多肽或其变体。
在某些实施方案中，所述药物包含所述gp96的C末端结构域或其活性片段或其变体、本发明的分离的多肽(或其变体)或融合蛋白中的一种或多种。
在某些实施方案中，所述自身免疫性疾病可以选自系统性红斑狼疮、1型糖尿病、类风湿性关节炎、强直性脊柱炎、多发性硬化症、银屑病、炎症性肠病、溃疡性结肠炎、克罗恩病、重症肌无力或多发性肌炎。
在某些实施方案中，所述药物用于预防和/或治疗系统性红斑狼疮或缓解系统性红斑狼疮的一种或多种症状(例如降低抗双链DNA抗体的水平，和/或降低尿蛋白的水平)。
在某些实施方案中，所述药物用于预防和/或治疗1型糖尿病或缓解1型糖尿病的一种或多种症状(例如降低血糖)。
在某些实施方案中，所述药物用于预防和/或治疗类风湿性关节炎或缓解类风湿性关节炎的一种或多种症状(例如减轻关节肿胀、压痛和/或疼痛)。
在某些实施方案中，所述药物用于预防和/或治疗强直性脊柱炎或缓解强直性脊柱炎的一种或多种症状(例如腰背痛、脊椎僵硬和/或关节炎)。
在某些实施方案中，所述受试者可以为哺乳动物，例如人或鼠。在某些实施方案中，所述受试者患有或被怀疑患有自身免疫性疾病，或者具有患上述疾病的风险。在某些实施方案中，所述受试者患有或被怀疑患有系统性红斑狼疮，或者具有患上述疾病的风险。在某些实施方案中，所述受试者患有或被怀疑患有1型糖尿病，或者具有患上述疾病的风险。在某些实施方案中，所述受试者患有或被怀疑患有类风湿性关节炎，或者具有患上述疾病的风险。在某些实施方案中，所述受试者患有或被怀疑患有强直性脊柱炎，或者具有患上述疾病的风险。
在另一方面，本发明还提供了用于在受试者中预防和/或治疗自身免疫性疾病或缓解自身免疫性疾病的一种或多种症状、或降低抗双链DNA抗体的水平、或降低尿蛋白的水平、或降低血糖的方法，所述方法包括向由此需要的受试者施用gp96的C末端结构域或其活性片段或其变体、或本发明的分离的多肽(或其变体)、融合蛋白、分离的核酸分子、载体、宿主细胞或药物组合物。
在某些实施方案中，所述C末端结构域由gp96蛋白的第550-803位氨基酸残基组成。在某些实施方案中，所述C末端结构域具有如SEQ ID NO:30所示的序列。
在某些实施方案中，所述gp96的C末端结构域的活性片段或其变体选自本发明的分离的多肽或其变体。
在某些实施方案中，向所述受试者施用所述gp96的C末端结构域或其活性片段或其变体、本发明的分离的多肽(或其变体)或融合蛋白中的一种或多种。
在某些实施方案中，所述自身免疫性疾病可以选自系统性红斑狼疮、1型糖尿病、类风湿性关节炎、强直性脊柱炎、多发性硬化症、银屑病、炎症性肠病、溃疡性结肠炎、克罗恩病、重症肌无力或多发性肌炎。
在某些实施方案中，所述方法用于预防和/或治疗系统性红斑狼疮或缓解系统性红斑狼疮的一种或多种症状(例如降低抗双链DNA抗体的水平，和/或降低尿蛋白的水平)。
在某些实施方案中，所述方法用于预防和/或治疗1型糖尿病或缓解1型糖尿病的一种或多种症状(例如降低血糖)。
在某些实施方案中，所述方法用于预防和/或治疗类风湿性关节炎或缓解类风湿性关节炎的一种或多种症状(例如减轻关节肿胀、压痛和/或疼痛)。
在某些实施方案中，所述方法用于预防和/或治疗强直性脊柱炎或缓解强直性脊柱炎的一种或多种症状(例如腰背痛、脊椎僵硬和/或关节炎)。
在某些实施方案中，所述受试者可以为哺乳动物，例如人或鼠。在某些实施方案中，所述受试者患有或被怀疑患有自身免疫性疾病，或者具有患上述疾病的风险。在某些实施方案中，所述受试者患有或被怀疑患有系统性红斑狼疮，或者具有患上述疾病的风险。在某些实施方案中，所述受试者患有或被怀疑患有1型糖尿病，或者具有患上述疾病的风险。在某些实施方案中，所述受试者患有或被怀疑患有类风湿性关节炎，或者具有患上述疾病的风险。在某些实施方案中，所述受试者患有或被怀疑患有强直性脊柱炎，或者具有患上述疾病的风险。
本发明的多肽(或其变体)、融合蛋白或药物组合物、或者所述gp96的C末端结构域或其活性片段或其变体可以配制成医学领域已知的任何剂型，例如，片剂、丸剂、混悬剂、乳剂、溶液、凝胶剂、胶囊剂、粉剂、颗粒剂、酏剂、锭剂、栓剂、注射剂(包括注射液、冻干粉剂)等形式。在一些实施方案中，本发明的多肽(或其变体)、融合蛋白或药物组合物可以配制成注射液或冻干粉剂。
此外，本发明的多肽(或其变体)或融合蛋白、或者所述gp96的C末端结构域 或其活性片段或其变体可以以单位剂量形式存在于药物组合物中，以便于施用。
本发明的多肽(或其变体)、融合蛋白或药物组合物、或者所述gp96的C末端结构域或其活性片段或其变体可以通过本领域已知的任何合适的方法来施用，包括但不限于，口服、口腔、舌下、眼球、局部、肠胃外、直肠、叶鞘内、内胞浆网槽内、腹股沟、膀胱内、局部(如，粉剂、药膏或滴剂)，或鼻腔途径。但是，对于许多治疗用途而言，优选的给药途径/方式是胃肠外给药(例如静脉注射，皮下注射，腹膜内注射，肌内注射)。技术人员应理解，给药途径和/或方式将根据预期目的而发生变化。在一个优选的实施方案中，本发明的多肽(或其变体)、融合蛋白或药物组合物、或者所述gp96的C末端结构域或其活性片段或其变体通过静脉输注或注射给予。
本发明所提供的多肽(或其变体)、融合蛋白或药物组合物、或者所述gp96的C末端结构域或其活性片段或其变体可以单独使用或联合使用，也可以与另外的药学活性剂(例如抗炎药物或免疫抑制剂)联合使用。这种另外的药学活性剂可以在施用本发明的多肽(或其变体)、融合蛋白或药物组合物、或者所述gp96的C末端结构域或其活性片段或其变体之前、同时或之后施用。
术语定义
在本发明中，除非另有说明，否则本文中使用的科学和技术名词具有本领域技术人员所通常理解的含义。并且，本文中所用的病毒学、生物化学、免疫学实验室操作步骤均为相应领域内广泛使用的常规步骤。同时，为了更好地理解本发明，下面提供相关术语的定义和解释。
如本文中所使用的，术语“gp96”又称为Grp94，是位于细胞内质网膜上的热休克蛋白90家族中的一员。gp96蛋白由N端结构域(N末端ATP结合结构域)、M结构域(带电中间结构域)以及C端结构域(C末端同源二聚结构域)组成。gp96是本领域技术人员公知的，其序列可参见各种公共数据库，例如NCBI GENBANK数据库登录号：AAH66656.1。
如本文中所使用的，当提及gp96蛋白的氨基酸序列时，其使用SEQ ID NO：7所示的序列来进行描述。例如，表述“gp96蛋白的第578-713位氨基酸残基”是指，SEQ ID NO：7所示的多肽的第578-713位氨基酸残基。然而，本领域技术人员理解，在gp96的氨基酸序列中，可天然产生或人工引入突变或变异，而不影响其生物学功能。 因此，在本发明中，术语“gp96”及其类似表述应包括所有此类序列，包括例如SEQ ID NO：7所示的序列以及其天然或人工的变体。并且，当描述gp96蛋白的序列片段时，其不仅包括SEQ ID NO：7的序列片段，还包括其天然或人工变体中的相应序列片段。例如，表述“gp96蛋白的第578-713位氨基酸残基”包括，SEQ ID NO：7的第578-713位氨基酸残基，以及其变体(天然或人工)中的相应片段。根据本发明，表述“相应序列片段”或“相应片段”是指，当对序列进行最优比对时，即当序列进行比对以获得最高百分数同一性时，进行比较的序列中位于等同位置的片段。
如本文中所使用的，术语“分离的”或“被分离的”指的是，从天然状态下经人工手段获得的。如果自然界中出现某一种“分离”的物质或成分，那么可能是其所处的天然环境发生了改变，或从天然环境下分离出该物质，或二者情况均有发生。例如，某一活体动物体内天然存在某种未被分离的多聚核苷酸或多肽，而从这种天然状态下分离出来的高纯度的相同的多聚核苷酸或多肽即称之为分离的。术语“分离的”或“被分离的”不排除混有人工或合成的物质，也不排除存在不影响物质活性的其它不纯物质。
如本文中所使用的，术语“载体(vector)”是指，可将多聚核苷酸插入其中的一种核酸运载工具。当载体能使插入的多核苷酸编码的蛋白获得表达时，载体称为表达载体。载体可以通过转化，转导或者转染导入宿主细胞，使其携带的遗传物质元件在宿主细胞中获得表达。载体是本领域技术人员公知的，包括但不限于：质粒；噬菌粒；柯斯质粒；人工染色体，例如酵母人工染色体(YAC)、细菌人工染色体(BAC)或P1来源的人工染色体(PAC)；噬菌体如λ噬菌体或M13噬菌体及动物病毒等。可用作载体的动物病毒包括但不限于，逆转录酶病毒(包括慢病毒)、腺病毒、腺相关病毒、疱疹病毒(如单纯疱疹病毒)、痘病毒、杆状病毒、乳头瘤病毒、乳头多瘤空泡病毒(如SV40)。一种载体可以含有多种控制表达的元件，包括但不限于，启动子序列、转录起始序列、增强子序列、选择元件及报告基因。另外，载体还可含有复制起始位点。
如本文中所使用的，术语“宿主细胞”是指，可用于导入载体的细胞，其包括但不限于，如大肠杆菌或枯草菌等的原核细胞，如酵母细胞或曲霉菌等的真菌细胞，如S2果蝇细胞或Sf9等的昆虫细胞，或者如纤维原细胞，CHO细胞，COS细胞，NSO细胞，HeLa细胞，BHK细胞，HEK 293细胞或人细胞等的动物细胞。
如本文中所使用的，对于杂交的“严格条件”是指形成特异性杂交体但不形成非特异性杂交体的条件。典型的严格条件例如可以举出在钾浓度约25mM～约50mM以及 镁浓度约1.0mM～约5.0mM中进行杂交的条件。作为示例，严格条件可以指在Tris-HCl(pH8.6)、25mM的KCl以及1.5mM的MgCl 2下进行杂交的条件，但不限于此。本领域技术人员能够通过改变杂交反应、杂交反应液的盐浓度等来容易地选择这样的条件。
如本文中所使用的，术语“同一性”用于指两个多肽之间或两个核酸之间序列的匹配情况。当两个进行比较的序列中的某个位置都被相同的碱基或氨基酸单体亚单元占据时(例如，两个DNA分子的每一个中的某个位置都被腺嘌呤占据，或两个多肽的每一个中的某个位置都被赖氨酸占据)，那么各分子在该位置上是同一的。两个序列之间的“百分数同一性”是由这两个序列共有的匹配位置数目除以进行比较的位置数目×100的函数。例如，如果两个序列的10个位置中有6个匹配，那么这两个序列具有60％的同一性。例如，DNA序列CTGACT和CAGGTT共有50％的同一性(总共6个位置中有3个位置匹配)。通常，在将两个序列比对以产生最大同一性时进行比较。这样的比对可通过使用，例如，可通过计算机程序例如Align程序(DNAstar,Inc.)方便地进行的Needleman等人(1970)J.Mol.Biol.48：443-453的方法来实现。还可使用已整合入ALIGN程序(版本2.0)的E.Meyers和W.Miller(Comput.Appl Biosci.，4:11-17(1988))的算法，使用PAM120权重残基表(weight residue table)、12的缺口长度罚分和4的缺口罚分来测定两个氨基酸序列之间的百分数同一性。此外，可使用已整合入GCG软件包(可在www.gcg.com上获得)的GAP程序中的Needleman和Wunsch(J MoI Biol.48:444-453(1970))算法，使用Blossum 62矩阵或PAM250矩阵以及16、14、12、10、8、6或4的缺口权重(gap weight)和1、2、3、4、5或6的长度权重来测定两个氨基酸序列之间的百分数同一性。
如本文中所使用的，术语“保守置换”意指不会不利地影响或改变包含氨基酸序列的蛋白/多肽的预期性质的氨基酸置换。例如，可通过本领域内已知的标准技术例如定点诱变和PCR介导的诱变引入保守置换。保守氨基酸置换包括用具有相似侧链的氨基酸残基替代氨基酸残基的置换，例如用在物理学上或功能上与相应的氨基酸残基相似(例如具有相似大小、形状、电荷、化学性质，包括形成共价键或氢键的能力等)的残基进行的置换。已在本领域内定义了具有相似侧链的氨基酸残基的家族。这些家族包括具有碱性侧链(例如，赖氨酸、精氨酸和组氨酸)、酸性侧链(例如天冬氨酸、谷氨酸)、不带电荷的极性侧链(例如甘氨酸、天冬酰胺、谷氨酰胺、丝氨酸、苏氨酸、酪 氨酸、半胱氨酸、色氨酸)、非极性侧链(例如丙氨酸、缬氨酸、亮氨酸、异亮氨酸、脯氨酸、苯丙氨酸、甲硫氨酸)、β分支侧链(例如，苏氨酸、缬氨酸、异亮氨酸)和芳香族侧链(例如，酪氨酸、苯丙氨酸、色氨酸、组氨酸)的氨基酸。因此，优选用来自相同侧链家族的另一个氨基酸残基替代相应的氨基酸残基。鉴定氨基酸保守置换的方法在本领域内是熟知的(参见，例如，Brummell等人，Biochem.32:1180-1187(1993)；Kobayashi等人Protein Eng.12(10):879-884(1999)；和Burks等人Proc.Natl Acad.Set USA 94:412-417(1997)，其通过引用并入本文)。
本文涉及的二十个常规氨基酸的编写遵循常规用法。参见例如，Immunology-A Synthesis(2nd Edition,E.S.Golub and D.R.Gren,Eds.,Sinauer Associates,Sunderland,Mass.(1991))，其以引用的方式并入本文中。在本发明中，术语“多肽”和“蛋白质”具有相同的含义且可互换使用。并且在本发明中，氨基酸通常用本领域公知的单字母和三字母缩写来表示。例如，丙氨酸可用A或Ala表示。
如本文中所使用的，术语“受试者”包括但不限于各种动物，特别是哺乳动物，例如人。在某些实施方案中，所述受试者(例如人)患有自身免疫性疾病。
如本文中所使用的，术语“药学上可接受的载体和/或赋形剂”是指，在药理学和/或生理学上与受试者和活性成分相容的载体和/或赋形剂，其是本领域公知的(参见例如Remington's Pharmaceutical Sciences.Edited by Gennaro AR,19th ed.Pennsylvania:Mack Publishing Company,1995)，并且包括但不限于：pH调节剂，表面活性剂，离子强度增强剂，维持渗透压的试剂，延迟吸收的试剂，稀释剂，佐剂，防腐剂，稳定剂等。例如，pH调节剂包括但不限于磷酸盐缓冲液。表面活性剂包括但不限于阳离子，阴离子或者非离子型表面活性剂，例如Tween-80。离子强度增强剂包括但不限于氯化钠。维持渗透压的试剂包括但不限于糖、NaCl及其类似物。延迟吸收的试剂包括但不限于单硬脂酸盐和明胶。稀释剂包括但不限于水，水性缓冲液(如缓冲盐水)，醇和多元醇(如甘油)等。佐剂包括但不限于铝佐剂(例如氢氧化铝)，弗氏佐剂(例如完全弗氏佐剂)等。防腐剂包括但不限于各种抗细菌试剂和抗真菌试剂，例如硫柳汞，2-苯氧乙醇，对羟苯甲酸酯，三氯叔丁醇，苯酚，山梨酸等。稳定剂具有本领域技术人员通常理解的含义，其能够稳定药物中的活性成分的期望活性(例如对PSD-95泛素化的抑制活性)，包括但不限于谷氨酸钠，明胶，SPGA，糖类(如山梨醇，甘露醇，淀粉，蔗糖，乳糖，葡聚糖，或葡萄糖)，氨基酸(如谷氨酸， 甘氨酸)，蛋白质(如干燥乳清，白蛋白或酪蛋白)或其降解产物(如乳白蛋白水解物)等。
如本文中所使用的，术语“治疗”是指，治疗或治愈疾病(例如自身免疫性疾病)，延缓疾病的一种或多种症状的发作，和/或延缓疾病的发展。
如本文中所使用的，术语“有效量”是指，可以有效实现预期目的的量。例如，治疗有效量可以是有效地或足以治疗或治愈疾病(例如自身免疫性疾病)，延缓疾病的一种或多种症状的发作和/或延缓疾病发展的量。这样的有效量可以由本领域技术人员或医生容易地确定，并且可以与预期目的、受试者的一般健康状况、年龄、性别、体重、待治疗的疾病的严重程度、并发症、施用方式等相关。这样的有效量的确定完全在本领域技术人员的能力范围内。
如本文中所使用的，本发明的多肽或其变体的生物学功能包括但不限于选自下列的一种或多种：
1)诱导调节性T细胞活化；
2)不诱导效应T细胞和B细胞活化；
3)在受试者中治疗自身免疫性疾病(例如系统性红斑狼疮、1型糖尿病、类风湿性关节炎、强直性脊柱炎)或缓解自身免疫性疾病的一种或多种症状；
4)在受试者中降低抗双链DNA抗体的水平；
5)在受试者中降低尿蛋白的水平；
6)在受试者中降低血糖。
有益效果
与现有技术相比，本发明的多肽(或其变体)和含有所述多肽(或其变体)的融合蛋白具有显著的有利方面。特别地，本发明的多肽(或其变体)和融合蛋白可特异性诱导调节性T细胞活化，且不诱导效应T细胞及B细胞活化，从而避免了全长gp96蛋白可能加重自身免疫性疾病进展的潜在风险。此外，本发明的多肽(或其变体)和融合蛋白诱导调节性T细胞活化的能力明显优于全长gp96蛋白，具有更优的免疫调节活性。因此，本发明的多肽(或其变体)和融合蛋白特别适用于自身免疫性疾病的治疗，具有重大的临床价值。
下面将结合附图和实施例对本发明的实施方案进行详细描述，但是本领域技术人员将理解，下列附图和实施例仅用于说明本发明，而不是对本发明的范围的限定。根据附图和优选实施方案的下列详细描述，本发明的各种目的和有利方面对于本领域技术人员来说将变得显然。
附图说明
图1为100μg不同gp96蛋白片段免疫小鼠后小鼠的调节性T细胞(Tregs)百分比(％CD3 +CD4 +CD25 +Foxp3 +Tregs/CD3 +CD4 +T细胞)。*，P<0.05；**,P<0.01
图2为300μg不同gp96蛋白片段免疫小鼠后小鼠的调节性T细胞(Tregs)百分比(％CD3 +CD4 +CD25 +Foxp3 +Tregs/CD3 +CD4 +T细胞)。*，P<0.05；***,P<0.001
图3为500μg不同gp96蛋白片段免疫小鼠后小鼠的调节性T细胞(Tregs)百分比(％CD3 +CD4 +CD25 +Foxp3 +Tregs/CD3 +CD4 +T细胞)。*，P<0.05；***,P<0.001
图4为300μg不同多肽片段和全长gp96免疫小鼠后小鼠的调节性T细胞(Tregs)百分比(％CD3 +CD4 +CD25 +Foxp3 +Tregs/CD3 +CD4 +T细胞)。**，peptides与gp96组相比P＜0.01
图5为30μg或300μg不同多肽片段和全长gp96联合卵清白蛋白(NP-OVA)免疫小鼠后活化的CD4 +T细胞百分比(INFγ +CD4 +T/CD4 +T)。**，P<0.01；***,P<0.001
图6为30μg或300μg不同多肽片段和全长gp96联合卵清白蛋白(NP-OVA)免疫小鼠后活化的CD8 +T细胞百分比(INFγ +CD8 +T/CD8 +T)。**，P<0.01；***,P<0.001
图7为300μg不同多肽片段和全长gp96免疫小鼠后小鼠血清中的抗OVA抗体IgG的水平。**，P<0.01
图8为100μg、300μg或500μg不同多肽片段和全长gp96免疫Lyn(-/-)小鼠后小鼠血清中抗dsDNA抗体的水平。相同剂量下，gp96组与PBS组相比P＜0.001(“***”)，peptide组与gp96组相比P＜0.05(“*”)
图9为100μg、300μg或500μg不同多肽片段和全长gp96免疫Lyn(-/-)小鼠后小鼠尿液中蛋白的水平。相同剂量下，gp96组与PBS组相比P＜0.001(“***”)，peptide组与gp96组相比P＜0.05(“*”)
图10为100μg、300μg或500μg不同多肽片段和全长gp96免疫后NOD小鼠预防模型T1D患病率。相同剂量下，peptide组与gp96组相比P＜0.05(“*”)或P＜0.01 (“**”)
图11为100μg、300μg或500μg不同多肽片段和全长gp96免疫后NOD小鼠预防模型血液中的血糖水平。相同剂量下，peptide组与gp96组相比P＜0.05(“*”)
图12为100μg、300μg或500μg不同多肽片段和全长gp96免疫后NOD小鼠预防模型脾脏细胞中活化的CD8 +T细胞百分比(INFγ +CD8 +T/CD8 +T)。相同剂量下，peptide组与gp96组相比P＜0.05(“*”)
图13为300μg不同多肽片段和全长gp96免疫后NOD小鼠治疗模型血液中的血糖水平。相同剂量下，peptide组与gp96组相比P＜0.05(“*”)
图14为300μg Peptide 1和其氨基酸缺失和替换突变免疫后NOD小鼠治疗模型血液中的血糖水平。
图15为300μg Peptide 15和其氨基酸缺失和替换突变免疫后NOD小鼠治疗模型血液中的血糖水平。
图16为不同多肽片段和全长gp96免疫后诱导性小鼠关节炎症模型中的类风湿性炎症指数检测结果。
图17为不同多肽片段和全长gp96免疫后诱导性小鼠强直性脊柱炎模型中的外周关节炎症指数检测结果。
序列信息
表1：本申请涉及的序列的信息描述于下面的表中。
Figure PCTCN2021119376-appb-000001
Figure PCTCN2021119376-appb-000002
Figure PCTCN2021119376-appb-000003
Figure PCTCN2021119376-appb-000004
Figure PCTCN2021119376-appb-000005
Figure PCTCN2021119376-appb-000006
Figure PCTCN2021119376-appb-000007
Figure PCTCN2021119376-appb-000008
Figure PCTCN2021119376-appb-000009
Figure PCTCN2021119376-appb-000010
Figure PCTCN2021119376-appb-000011
Figure PCTCN2021119376-appb-000012
Figure PCTCN2021119376-appb-000013
具体实施方式
现参照下列意在举例说明本发明(而非限定本发明)的实施例来描述本发明。
本领域技术人员知晓，实施例以举例方式描述本发明，且不意欲限制本申请所要求保护的范围。实施例中的实验方法，如无特殊说明，均为常规方法。实施例中未注明具体条件者，按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者，均为可以通过市购获得的常规产品。实施例中的定量实验，均设置三次重复实验，结果取平均值。
以下实施例中所涉及的实验材料来源如下：
雌性Lyn(-/-)敲除鼠系统性红斑狼疮模型参见如下文献：Hibbs ML,et al.Multiple defects in the immune system of Lyn-deficient mice,culminating in autoimmune disease.Cell(1995)83(2):301–11；Yu CC,Yen TS,Lowell CA,DeFranco AL.Lupus-like kidney disease in mice deficient in the Src family tyrosine kinases Lyn and Fyn.Curr Biol.2001Jan 9；11(1):34-8.
雌性NOD/LTJ小鼠参见如下文献：Terry L.et al.I The Nonobese Diabetic Mouse as a Model of Autoimmune Diabetes:Immune Dysregulation Gets the NOD.Immunity,December,1997，Vol.7,727-738；Michelle Solomon,Nora Sarvetnick,et al.The Pathogenesis of Diabetes in the NOD Mouse.Immunology,2004，84:239-64.
Sf9细胞购自Invitrogen公司，目录号：11496-015；
pFastBac TM1质粒购自Invitrogen公司，产品目录号：10359-016；
DH10Bac TM感受态细胞购自Invitrogen公司，产品目录号：10361-012；
Insect-XPRESSTM Protein-free Insect Cells medium with L-Glutamine购自LONZA公司，产品目录号：12-730Q；
超滤管购自Merck Millipore公司，产品目录号：UFC905096；
ELISA试剂盒购自eBioscience公司，产品目录号：BMS614INST；
Ni亲和层析预装柱购自阿拉丁公司，产品目录号：N5289-01；
Superdex 200 10/300 GL分子筛层析柱购自GE公司，产品目录号：17517501；
大肠杆菌DH10Bac感受态细胞购自北京原平皓生物技术有限公司，产品目录号：CL108-01。
实施例1：全长gp96或不同gp96截短体的制备
1.重组质粒的构建。
含有全长gp96或不同gp96截短体的编码序列的重组质粒pFastBac1-DNAs由金斯瑞生物科技股份有限公司合成。所涉及的全长gp96或不同gp96截短体的氨基酸序列及编码核酸序列参见表1。将重组质粒分别转化至DH10Bac TM感受态细胞，经重组筛选得到重组杆粒DNA。所有gp96蛋白片段和多肽的C端都带有6xHis标签，标签的DNA序列为CACCACCACCATCACCAC(SEQ ID NO:63)。
2.全长gp96或不同gp96截短体的表达。
2.1将重组杆粒DNA共转染贴壁Sf9细胞(每8×10 5个Sf9细胞约转染2μg重组质粒；共转染过程中，转染试剂为Cellfectin II reagent(购自Life technologies，产品目录号：10362-100))，27℃孵育72h，离心，上清液即为P1代病毒。
2.2将Sf9细胞悬浮液1(含8×10 6个Sf9细胞)27℃培养1～5h，得到贴壁培养细胞；然后向所述贴壁培养细胞中加入P1代病毒(剂量为0.05～0.1MOI)，27℃孵育72h，4000rpm离心5min，上清液即为P2代病毒。
2.3向Sf9细胞悬浮液2(含8×10 6个Sf9细胞)中加入P2代病毒(剂量为0.05～0.1MOI)，27℃、100～120rpm培养72h，4000rpm离心5min，上清液即为P3代病毒。
3.全长gp96或不同gp96截短体的纯化。
3.1向300ml的Sf9细胞悬浮液3(含Sf9细胞2～4×10 6个/ml)中加入P3代病毒(剂量为0.05MOI)，27℃、100～120rpm培养72～96h，得到悬浮液。
3.2取所述悬浮液，7000rpm离心20min，获得上清液1。
3.3取所述上清液1，经0.22mm滤膜过滤，获得上样液。
3.4将所述上样液上样于Ni亲和层析柱。上样流速控制在1ml/min，然后用不含咪唑的Tris-HCl缓冲液冲洗，再用含有咪唑的Tris-HCl缓冲液洗脱并收获洗脱液。将洗脱液用截留分子量为10KD的超滤管进行超滤浓缩，得到1ml左右的浓缩液。所述浓缩液即含有重组gp96C端蛋白。
3.5将步骤4得到的浓缩液上样于Superdex 200 10/300 GL分子筛层析柱(流速为0.25ml/min)，然后用pH7.5、含150mM NaCl的PBS缓冲液洗涤(流速为0.25ml/min)，收集为相应蛋白峰的穿透液，通过SDS-PAGE检测相应的蛋白，并利用抗His-tag抗体(购自上海碧云天生物技术有限公司)通过western blotting进一步对纯化的蛋白进行鉴定。进一步采用截留分子量为10KD的超滤管进行超滤浓缩，得到分别含有不同gp96蛋白片段和多肽的溶液。采用BCA法测定蛋白和多肽的溶液中的蛋白浓度，最后分装，蛋白浓度为1mg/ml，贮存于-80℃。
实施例2：全长gp96或不同gp96截短体诱导小鼠调节性T细胞活性的评价
本实施例考察gp96全长蛋白(SEQ ID NO:7)、截短体gp96-N(SEQ ID NO:8)、 gp96-M(SEQ ID NO:10)、gp96-N+M(SEQ ID NO:9)、gp96-C(SEQ ID NO:11)及gp96-C+M(SEQ ID NO:12)诱导小鼠产生调节性T细胞的情况。在以上各蛋白或多肽的C端添加6xHis标签。其中，gp96-N对应于全长蛋白的第550-578位氨基酸残基；gp96-M对应于全长蛋白的第578-713位氨基酸残基；gp96-C对应于全长蛋白的第713-803位氨基酸残基。
1、小鼠分组免疫
将105只六周龄体重为14～16g的C57BL/6小鼠(购自北京维通利华实验动物技术有限公司)随机分成gp96处理组、gp96-N处理组、gp96-M处理组、重组gp96-N+M处理组重组、gp96-C处理组、gp96-C+M处理组和对照组(每组5只小鼠)，分别进行如下处理：
gp96-N处理组：小鼠生长至第9周龄，腹部皮下注射实施例1制备获得的经纯化的gp96-N的溶液，记为实验第1天；实验第8天后，再次腹部皮下注射实施例1制备获得的经纯化的gp96N的溶液；实验第22天，再次腹部皮下注射实施例1制备获得的经纯化的gp96-N的溶液。每次注射剂量均为100μg，300μg或500μg gp96-N/只小鼠。
gp96-M处理组：小鼠生长至第9周龄，腹部皮下注射实施例1制备获得的经纯化的gp96-M的溶液，记为实验第1天；实验第8天后，再次腹部皮下注射实施例1制备获得的经纯化的gp96-M的溶液；实验第22天，再次腹部皮下注射实施例1制备获得的经纯化的gp96-M的溶液。每次注射剂量均为100μg，300μg或500μg gp96-M/只。
gp96-N+M处理组：小鼠生长至第9周龄，腹部皮下注射实施例1制备获得的经纯化的gp96-N+M的溶液，记为实验第1天；实验第8天后，再次腹部皮下注射实施例1制备获得的经纯化的gp96-N+M溶液；实验第22天，再次腹部皮下注射实施例1制备的经纯化的gp96-N+M的溶液。每次注射剂量均为100μg，300μg或500μg gp96-N+M/只。
gp96-C处理组：小鼠生长至第9周龄，腹部皮下注射实施例1制备的经纯化的gp96-C，记为实验第1天；实验第8天后，再次腹部皮下注射实施例1制备的经纯化的gp96-C的溶液；实验第22天，再次腹部皮下注射实施例1制备的经纯化的gp96-C的溶液。每次注射剂量均为100μg，300μg或500μg gp96-C/只。
gp96-C+M处理组：小鼠生长至第9周龄，腹部皮下注射实施例1制备的经纯化的gp96-C+M，记为实验第1天；实验第8天后，再次腹部皮下注射实施例1制备的经纯化的gp96-C+M的溶液；实验第22天，再次腹部皮下注射实施例1制备的经纯化的gp96C-3的溶液。每次注射剂量均为100μg，300μg或500μg gp96-C+M/只。
全长gp96处理组：小鼠生长至第9周龄，腹部皮下注射实施例1制备的经纯化的gp96-C+M，记为实验第1天；实验第8天后，再次腹部皮下注射实施例1制备的经纯化的gp96-C+M的溶液；实验第22天，再次腹部皮下注射实施例1制备的全长gp96的溶液。每次注射剂量均为100μg，300μg或500μg gp96/只。
对照组：实验第1天腹部皮下注射pH7.2、0.01mol/L PBS缓冲液，实验第8天，再次腹部皮下注射pH7.2、0.01mol/L PBS缓冲液；实验第22天，再次腹部皮下注射pH7.2、0.01mol/L PBS缓冲液。每次注射PBS剂量均为100μl/只，300μg或500μl/只。
2、免疫效果评价
在第25天处死小鼠，取小鼠脾脏分离制备小鼠脾脏淋巴细胞，利用流式细胞仪分析小鼠的调节性T细胞(Tregs)百分比(％CD3 +CD4 +CD25 +Foxp3 +Tregs/CD3 +CD4 +T细胞)。调节性T细胞的分离和检测方法详见Xinghui Li,et al.2013.Induction of regulatory T cells by high-dose gp96 suppresses murine liver immune hyperactivation.PLoS One.8(7):e68997。
检测结果如图1-3所示，图1-3分别为100μg、300μg和500μg不同gp96蛋白片段免疫小鼠后小鼠的调节性T细胞(Tregs)百分比。结果表明，100μg，300μg或500μg gp96-C、gp96-C+M蛋白免疫的小鼠调节性T细胞的百分比显著高于对照组(PBS)或gp96-N、gp96-M、gp96-N+M免疫组(P<0.05或P<0.001)，而且gp96-C和gp96-C+M蛋白免疫组调节性T细胞水平明显高于全长gp96免疫组(P<0.05)，而gp96-N、gp96-M、gp96-N+M蛋白和对照组处理小鼠的调节性T细胞百分比无显著差异。
实施例3：基于gp96蛋白的C端结构域的不同截短体的制备及其诱导小鼠调节性T细胞活性的评价
1、不同多肽片段的设计
gp96全长的C末端共有255个氨基酸残基，分别截除分成17个不同的多肽片段： Peptide 1-Peptide 17，它们的氨基酸序列分别如SEQ ID NOs:30-46所示。在以上各多肽的C端添加6xHis标签，利用实施例1中的方法分别表达和制备上述17种多肽。
2、小鼠分组免疫
将95只六周龄体重为14～16g的C57BL/6小鼠随机分成19组，分别设Peptide 1-Peptide 17实验组、PBS和gp96对照组，每组5只小鼠。
小鼠生长至第9周龄，实验第1天腹部皮下注射相应的蛋白(多肽)或PBS，实验第8天，再次腹部皮下注射；实验第22天，再次腹部皮下注射。每次注射剂量均为300μg/只。
3、效果评价
第25天处死小鼠，取小鼠脾脏分离制备小鼠脾脏淋巴细胞，利用流式细胞仪分析不同重组多肽片段免疫后小鼠调节性T细胞百分比。调节性T细胞的分离和检测方法如实施例2。
检测结果如图4，结果表明，Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15处理组，小鼠调节性细胞的百分比显著高于对照组(PBS)(P<0.001)，且均高于全长gp96处理组(P<0.01)。并且可以看出，Peptide 15所包含的氨基酸序列(gp96全长蛋白的第578-713位氨基酸残基)是活化调节性T细胞的必要序列。
实施例4：基于gp96蛋白的C端结构域的不同截短体诱导小鼠效应T细胞活性的评价
1、小鼠分组免疫
将110只六周龄体重为14～16g的C57BL/6小鼠随机分成22组，分别设Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽、全长gp96联合卵清白蛋白(NP-OVA)(购自北京博奥派克生物科技有限公司，货号：T-5051-100*100mg)实验组、单独NP-OVA或PBS对照组(每组5只小鼠)。
小鼠生长至第9周龄，实验第1天腹部皮下注射相应的多肽或全长gp96联合NP-OVA，或单独NP-OVA或PBS免疫，实验第8天，再次腹部皮下注射；实验第22天，再次腹部皮下注射。每次注射多肽或全长gp96注射剂量均为30μg或300μg/只小鼠，OVA蛋白的剂量为20μg/只小鼠。
2、效果评价
在第25天处死小鼠，分离小鼠的脾脏细胞，利用流式细胞仪分析免疫后小鼠活化的CD4 +T细胞、CD8 +T细胞百分比。活化的CD4 +T细胞、CD8 +T细胞的分离和检测方法详见Xinghui Li,et al.2013.Induction of regulatory T cells by high-dose gp96 suppresses murine liver immune hyperactivation.PLoS One.8(7):e68997。
活化的CD4 +T细胞、CD8 +T细胞百分比检测结果分别如图5和图6所示，结果表明，30μg和300μg免疫剂量的Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽片段处理组中小鼠活化的CD4 +T细胞和CD8 +T细胞的百分比均与对照组(PBS)无明显差异，而30μg免疫剂量的全长gp96组小鼠活化的CD4 +T细胞和CD8 +T细胞的百分比显著高于对照组(PBS)(P<0.001)和OVA免疫组(P<0.01)，300μg免疫剂量的全长gp96组小鼠活化的CD4 +T细胞和CD8 +T细胞的百分比显著高于对照组(PBS)(P<0.01)，这表明多肽片段免疫不会活化效应T细胞，而全长gp96可明显活化效应T细胞。
进一步通过ELISA检测300μg不同多肽片段和全长gp96免疫小鼠后小鼠血清中的抗OVA抗体IgG的水平，检测方法详见Bettina Eide Holm,et al.2015.Antibldies with specificity for native and denatured forms of ovalbumin differ in reactivity between enzyme-linked immunosorbent assays.APMIS.123(2):136-45。
检测结果如图7所示，结果表明300μg免疫剂量的Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽片段处理组中小鼠血清抗OVA抗体水平与对照组(PBS)无明显差异，并明显低于全长gp96免疫小鼠(所有P<0.05)，这表明多肽片段免疫不会活化效应B细胞。
实施例5：基于gp96蛋白的C端结构域的不同截短体在治疗系统性红斑狼疮中的应用
1、小鼠分组免疫
将300只六周龄体重为14～16g的雌性Lyn(-/-)小鼠随机分成Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽、全长gp96免疫组和对照组(PBS)(每组10只)，分别进行如下处理：小鼠生长至第7周龄、第8周龄、第10周龄、第12周龄、第14周龄、第16周龄时，分别在小鼠腹 部皮下注射实施例1和实施例3制备的经纯化的重组多肽、全长gp96或PBS，每次注射剂量/只小鼠为100μg、300μg或500μg。
小鼠生长至20周龄时，眼眶取血200μl。室温静置30min，3000rpm离心20min，取上清。
2、抗双链DNA抗体滴度的分析
血清中抗双链DNA抗体的水平采用酶联免疫吸附(ELISA)方法测定，步骤如下：
2.1向96孔酶标板(购自Nunc,Rochester NY,USA)中加入2.5μg/ml的小牛胸腺dsDNA标准品(购自Sigma Aldrich,USA，货号：D8899-1MG)，每孔100μl。4℃包被过夜。
2.2加入2％牛血清白蛋白(购自Invitrogen,USA)100μl，37℃孵育60分钟。
2.3加入血清样本50μl(1：50比例稀释)和抗dsDNA抗体标准品(购自Chemicon International,USA，clone号：16-13),37℃孵育60分钟。
2.4弃去孔内液体，每孔加入200μl的1×洗涤液(PBST，PBS按0.1％加入Triton-X100)，静置30秒，甩干，重复洗涤5次。最后在吸水纸上拍干。
2.5加入HRP标记的抗小鼠二抗(购自中杉金桥，1：5000稀释)，每孔50μl。37℃孵育60分钟。
2.6弃去孔内液体，每孔加入200μl的1×洗涤液，静置30秒，甩干，重复洗涤5次。最后在吸水纸上拍干。
2.7每孔加入100μl底物(1×TMB ELISA Substrate Solution，购自eBioscience，货号：00-4201-56)。37℃孵育15分钟。
2.8弃去孔内液体，每孔加入50μl终止液(2M H 2SO 4)，混匀，酶标仪上450nm波长下读数。测定应在加终止液后15分钟以内进行。
3、尿蛋白的测定
尿蛋白检测试剂盒购自南京建成生物工程研究所(货号：C035-2)
3.1取三个管，分别标记为空白管，标准管和测定管。空白管加入双蒸水0.05ml，CBB试剂3.0ml。标准管加入563mg/L蛋白标准液0.05ml，CBB试剂3.0ml。测定管加入尿液样本0.05ml，CBB试剂3.0ml。
3.2充分混匀，放置5分钟。分光光度计用波长595nm检测各管的吸光度。
尿蛋白浓度(mg/L)＝(测定OD值－空白OD值)/(标准OD值－空白OD值)×标准品浓度
4、效果评价
小鼠的抗双链DNA抗体检测结果见图8。结果表明，Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽治疗小鼠的抗双链DNA抗体滴度显著小于对照组(PBS)(P<0.001)，同时也明显低于全长gp96治疗组(P<0.05)。这说明多肽治疗系统性红斑狼疮的效果优于全长gp96。
小鼠的尿蛋白检测结果见图9。结果表明，Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽治疗小鼠的尿蛋白水平显著低于对照组(PBS)(P<0.001)，同时也明显低于全长gp96治疗组(P<0.05)。这说明多肽治疗系统性红斑狼疮的效果优于全长gp96。
实施例6：基于gp96蛋白的C端结构域的不同截短体在预防1型糖尿病中的应用
1、小鼠免疫
将300只六周龄体重为14～16g的NOD小鼠预防模型随机分成Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽、全长gp96免疫组和对照组(PBS)(每组10只)，分别进行如下处理：小鼠生长至第7周龄、第8周龄、第10周龄、第12周龄、第14周龄时，分别在小鼠腹部皮下注射实施例1和实施例3制备的经纯化的重组多肽、全长gp96或PBS，每次注射剂量/只小鼠分别为100μg、300μg或500μg。
从NOD小鼠第9周龄开始监测小鼠血糖值，取小鼠尾静脉血1滴，用血糖仪(德国罗氏公司
Figure PCTCN2021119376-appb-000014
Performa)参照说明书测定血糖值，并统计患病率。以血糖值>13.3mmol/L且持续2次以上诊断为糖尿病(T1D)。
2、效果评价
小鼠患病指数结果见图10，结果表明，Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽免疫小鼠T1D的患病率明显低于全长gp96免疫小鼠(P<0.05或P＜0.01)，对照小鼠(PBS)在11-14周龄均发病。
小鼠血糖浓度检测结果见图11，结果表明，Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽免疫的小鼠的血糖浓度显著低于全长gp96免疫组(P<0.05)。
在小鼠20周龄时处死小鼠，分离小鼠的脾脏细胞，利用流式细胞仪分析免疫后小鼠活化的CD8 +T细胞百分比，检测结果见图12。结果表明，Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽片段处理组中小鼠活化的CD8 +T细胞的百分比明显低于全长gp96组小鼠(P<0.05)。
上述结果表明，上述多肽对1型糖尿病的预防效果明显优于全长gp96。
实施例7：基于gp96蛋白的C端结构域的不同截短体在治疗1型糖尿病中的应用
1、小鼠免疫
将100只六周龄体重为14～16g的NOD小鼠治疗模型随机分成Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽、全长gp96免疫组和对照组(PBS)(每组10只)，分别进行如下处理：小鼠生长至第14周龄、第15周龄、第17周龄、第19周龄、第21周龄时，分别在小鼠腹部皮下注射实施例1和实施例3制备的经纯化的多肽、全长gp96或PBS，每次注射剂量/只小鼠为300μg。
从最后一次免疫后的第1周开始监测小鼠血糖值，每周检测1次。取小鼠尾静脉血1滴，用血糖仪(德国罗氏公司
Figure PCTCN2021119376-appb-000015
Performa)参照说明书测定血糖值。
2、效果评价
小鼠血糖浓度检测结果见图13。结果表明，Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽免疫后小鼠的血糖浓度随着时间变化而逐渐降低，最终浓度显著低于对照组(PBS)(P<0.001)，同时所有多肽免疫组小鼠血糖水平也明显低于全长gp96免疫组(P<0.05)。
上述结果表明，用多肽免疫小鼠，能够有效的治疗小鼠的TID，其治疗效果优于全长gp96。
实施例8：突变多肽片段在治疗1型糖尿病中的应用
1、突变多肽片段的表达
将上述Peptide 1和Peptide 15多肽随机选取三个氨基酸位点突变为丙氨酸(Ala)，分别记做Peptide 1m-1(SEQ ID NO:55)、Peptide 1m-2(SEQ ID NO:56)、Peptide 15m-1(SEQ ID NO:59)、Peptide 15m-2(SEQ ID NO:60)，再将Peptide 1、Peptide 15中三个氨基酸位点缺失，分别记做Peptide 1d-1(SEQ ID NO:57)、Peptide 1d-2(SEQ ID NO:58)、Peptide15d-1(SEQ ID NO:61)、Peptide15d-2(SEQ ID NO:62)。在以上各蛋白或多肽的C端添加6xHis标签。重组质粒由金斯瑞生物科技股份有限公司合成，然后按实施例1进行多肽的表达和纯化。
2、小鼠免疫
将60只六周龄体重为14～16g的NOD小鼠治疗模型随机分成Peptide 1、Peptide 1m-1、Peptide 1m-2、Peptide 1d-1、Peptide 1d-2、Peptide 15、Peptide 15m-1、Peptide 15m-2、Peptide 15d-1、Peptide 15d-2多肽免疫组(每组10只)，分别进行如下处理：小鼠生长至第14周龄、第15周龄、第17周龄、第19周龄、第21周龄时，分别在小鼠腹部皮下注射按实施例1方法制备的多肽，每次注射剂量/只小鼠为300μg。
从最后一次免疫后的第1周开始监测小鼠血糖值，每周检测1次。取小鼠尾静脉血1滴，用血糖仪(德国罗氏公司
Figure PCTCN2021119376-appb-000016
Performa)参照说明书测定血糖值。
3、效果评价
Peptide 1氨基酸缺失和替换突变多肽免疫小鼠血糖浓度检测结果见图14，结果表明，突变的多肽免疫后小鼠的血糖浓度与未突变多肽没有明显区别，说明突变多肽和未突变多肽具有相同的治疗功能。
Peptide 15氨基酸缺失和替换突变多肽免疫小鼠血糖浓度检测结果见图15，结果表明，突变后的多肽免疫后小鼠的血糖浓度与未突变多肽没有明显区别，说明某些突变多肽和未突变多肽具有相同的治疗功能。
上述结果表明，本发明的多肽能够在一定程度上耐受氨基酸突变，维持其治疗自身免疫性疾病的活性。
实施例9：基于gp96蛋白的C端结构域的不同截短体在治疗诱导性小鼠关节炎症中的应用
1、小鼠分组免疫
将310只六周龄体重为14～16g的雌性DBA/1小鼠(北京维通利华实验动物技术有限公司)随机分成Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽、全长gp96免疫组、对照组(PBS)和模型组(每组10只)，除10只正常对照组外，其余300只小鼠进行CIA造模。将10mg牛Ⅱ型胶原溶于0.01mmol/L的醋酸溶液5mL,4℃摇床过夜,取5mL含2mg/mL的完全弗氏佐剂等体积混合，充分乳化制得抗原乳剂，并置于冰箱4℃保存备用。首次免疫于小鼠尾根部皮下注射抗原乳剂0.1mL，造模第21天使用0.1mLⅡ型胶原和不完全弗氏佐剂混合的乳剂进行加强免疫一次，正常组同法注射等体积的生理盐水。二次免疫后的第8天分别进行如下处理：小鼠生长至第10周龄、第11周龄、第13周龄，分别在小鼠腹部皮下注射实施例1和实施例3制备的重组多肽、全长gp96或PBS，每次注射剂量/只小鼠为100μg、300μg或500μg。
指标检测，关节炎指数:小鼠给药后第0、5、10、15、20、25、30天给予关节炎症指数评分,评分标准：0分:没有明显的关节红肿；1分:踝关节或趾关节轻度红肿；2分:从趾关节到踝关节轻度红肿；3分:从趾关节到踝关节中度红胀；4分:严重的踝关节到整个足掌的红肿,每只小鼠最高评分16分。足掌厚度:小鼠给药后第0、5、10、15、20、25、30天给予选取肿胀的足掌给予测肿胀的厚度,用游标卡尺选取肿胀最甚处测量,单位为mm。
2、效果评价
小鼠关节炎症指数结果见图16，结果表明，Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽免疫后小鼠的关节炎症指数显著低于模型组(P<0.001)，同时也低于全长gp96治疗组(P<0.05)。此外，足掌厚度的检测结果显示，Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽免疫后小鼠的足掌厚度显著低于模型组(P<0.001)，同时也低于全长gp96治疗组(P<0.05)。注射剂量为100μg或500μg的小鼠治疗类风湿也得到类似的治疗结果。上述结果表明，用多肽免疫小鼠，能够有效的治疗小鼠的诱导性关节炎症，其治疗效果优于全长gp96。
实施例10：基于gp96蛋白的C端结构域的不同截短体在治疗诱导性强直性脊柱炎中的应用
1、小鼠分组免疫
将310只六月龄的雌性BALB/c小鼠随机分成Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽、全长gp96免疫组、对照组(PBS)和模型组(每组10只)，除对照组外，其余300只小鼠进行蛋白聚糖(PG)诱导造模，诱导小鼠强制性脊柱炎。将100μg软骨蛋白聚糖(购自Sigma，货号：P5864)与1gg DDA佐剂(购自Avanti，货号：890810p)混合在200μL的生理盐水中，在第0、21和42天注射入小鼠的腹腔。三次免疫后的第8天开始分别进行如下处理：每周分别在小鼠腹部皮下注射实施例1和实施例3制备的重组多肽、全长gp96或PBS，每次注射剂量/只小鼠为100μg、300μg或500μg。
指标检测：第三次造模免疫后每周进行外周关节炎的记录，连续7周。外周关节炎指数评分标准：无任何炎性肿胀为0分，一个脚趾受累表现肿胀为1分，大于一个脚趾受累为2分，足趾僵直失去关节功能为3分，踝关节肿胀僵直为4分，对模型小鼠的四肢进行评分，总评分在0-16之间。
2、效果评价
结果如图17所示，Peptide 1、Peptide 2、Peptide 3、Peptide 4、Peptide 8、Peptide 13、Peptide 14、Peptide 15多肽免疫后强直性脊柱炎模型小鼠的外周关节炎指数显著低于模型组(P<0.001)，同时也低于全长gp96治疗组(P<0.05)，上述结果表明，用上述多肽免疫小鼠，能够有效的治疗小鼠的诱导性强直性脊柱炎，其治疗效果优于全长gp96。
尽管本发明的具体实施方式已经得到详细的描述，但本领域技术人员将理解：根据已经公布的所有教导，可以对细节进行各种修改和变动，并且这些改变均在本发明的保护范围之内。本发明的全部分为由所附权利要求及其任何等同物给出。

Claims (20)

  1. 一种分离的多肽或其变体，其中，所述多肽由gp96蛋白的至少136个连续氨基酸残基组成，且包含：gp96蛋白的第578-713位氨基酸残基；
    其中，所述变体与其所源自的多肽相异仅在于1个或几个(例如，1个、2个、3个、4个或5个)氨基酸残基的置换、缺失或添加，且保留了其所源自的多肽的生物学功能(例如诱导调节性T细胞活化，不诱导效应T细胞和B细胞活化，预防和/或治疗自身免疫性疾病或缓解自身免疫性疾病的一种或多种症状，降低抗双链DNA抗体的水平，降低尿蛋白的水平，和/或降低血糖)。
  2. 权利要求1所述的分离的多肽或其变体，其中，所述分离的多肽包含：gp96蛋白的第578-713位氨基酸残基、第578-743位氨基酸残基、第578-773位氨基酸残基、第578-803位氨基酸残基、第550-713位氨基酸残基、第550-743位氨基酸残基、第550-773位氨基酸残基或第550-803位氨基酸残基。
  3. 权利要求1或2所述的分离的多肽或其变体，其中，所述gp96蛋白具有如SEQ ID NO:7所示的序列。
  4. 权利要求1-3任一项所述的分离的多肽或其变体，其中，所述分离的多肽包含选自下列的氨基酸序列：SEQ ID NOs:30、31、32、33、37、42、43、44。
  5. 权利要求1-4任一项所述分离的多肽或其变体，其中，所述变体与其所源自的多肽相异仅在于1个、2个或3个氨基酸残基的置换、缺失或添加；
    优选地，所述置换包括将所述氨基酸残基替换为丙氨酸(A)。
  6. 权利要求1-5任一项所述的分离的多肽或其变体，其中，所述变体包含选自下列的氨基酸序列：SEQ ID NOs:55-62。
  7. 一种融合蛋白，其包含权利要求1-6任一项所述的分离的多肽或其变体和另外的多肽；
    优选地，所述另外的多肽任选地通过接头连接至所述多肽或其变体的N端或C端；
    优选地，所述另外的多肽选自蛋白标签、靶向部分或其任意组合。
  8. 一种分离的核酸分子，其包含编码权利要求1-6任一项所述的分离的多肽或其变体，或权利要求7所述的融合蛋白的核苷酸序列；
    优选地，所述分离的核酸分子包含选自下列的核苷酸序列：(i)SEQ ID NOs:13-16、20、25-27、47-54任一项所示的序列；(ii)与(i)所述序列相比具有至少70％、至少75％、至少80％、至少85％、至少90％、至少95％、至少99％的序列同一性的序列；(iii)在严格条件下与(i)或(ii)中所述的序列杂交的序列；或(iv)(i)或(ii)中所述的序列的互补序列。
  9. 一种载体，其包含权利要求8所述的分离的核酸分子。
  10. 一种宿主细胞，其包含权利要求8所述的分离的核酸分子或权利要求9所述的载体。
  11. 一种药物组合物，其包含权利要求1-6任一项所述的分离的多肽或其变体、权利要求7所述的融合蛋白、权利要求8所述的分离的核酸分子、权利要求9所述的载体或权利要求10所述的宿主细胞，以及药学上可接受的载体和/或赋形剂；
    优选地，所述药物组合物包含权利要求1-6任一项所述的分离的多肽或其变体、权利要求7所述的融合蛋白中的一种或多种。
  12. 权利要求11所述的药物组合物，其中，所述药物组合物任选地还包含另外的药学活性剂；
    优选地，所述另外的药学活性剂为具有治疗自身免疫性疾病活性的药物，例如抗炎药物或免疫抑制剂。
  13. 权利要求1-6任一项所述的分离的多肽或其变体、权利要求7所述的融合蛋白、权利要求8所述的分离的核酸分子、权利要求9所述的载体或权利要求10所述的宿主细胞、或权利要求11或12所述的药物组合物在制备药物中的用途，所述药物用于：
    (i)在受试者中预防和/或治疗自身免疫性疾病或缓解自身免疫性疾病的一种或多种症状；
    (ii)在受试者中降低抗双链DNA抗体的水平；
    (iii)在受试者中降低尿蛋白的水平；和/或
    (iv)在受试者中降低血糖。
  14. gp96蛋白的C末端结构域(即，C末端同源二聚结构域)或其活性片段或其变体在制备药物中的用途，所述药物用于：
    (i)在受试者中预防和/或治疗自身免疫性疾病或缓解自身免疫性疾病的一种或多种症状；
    (ii)在受试者中降低抗双链DNA抗体的水平；
    (iii)在受试者中降低尿蛋白的水平；和/或
    (iv)在受试者中降低血糖。
  15. 权利要求14所述的用途，其中，所述活性片段包含gp96蛋白的第578-713位氨基酸残基；
    优选地，所述活性片段包含：gp96蛋白的第578-713位氨基酸残基、第578-743位氨基酸残基、第578-773位氨基酸残基、第578-803位氨基酸残基、第550-713位氨基酸残基、第550-743位氨基酸残基、或第550-773位氨基酸残基；
    优选地，所述活性片段包含选自下列的氨基酸序列：SEQ ID NOs:31、32、33、37、42、43、44；
    优选地，所述活性片段选自权利要求1-6任一项中所述的分离的多肽。
  16. 权利要求14或15所述的用途，其中，所述变体与其所源自的多肽相异仅在于1个或几个(例如，1个、2个、3个、4个或5个)氨基酸残基的置换、缺失或添 加，且保留了其所源自的多肽的生物学功能(例如诱导调节性T细胞活化，不诱导效应T细胞和B细胞活化的活性，预防和/或治疗自身免疫性疾病或缓解自身免疫性疾病的一种或多种症状，降低抗双链DNA抗体的水平，降低尿蛋白的水平，和/或降低血糖)；
    优选地，所述变体与其所源自的多肽相异仅在于1个、2个或3个氨基酸残基的置换、缺失或添加；优选地，所述置换包括将所述氨基酸残基替换为丙氨酸(A)；
    优选地，所述变体包含选自下列的氨基酸序列：SEQ ID NOs:55-62；
    优选地，所述变体选自权利要求1-6任一项中所述的变体。
  17. 权利要求13-16任一项所述的用途，其中，所述自身免疫性疾病选自系统性红斑狼疮、1型糖尿病、类风湿性关节炎、强直性脊柱炎、多发性硬化症、银屑病、炎症性肠病、溃疡性结肠炎、克罗恩病、重症肌无力或多发性肌炎。
  18. 权利要求13-17任一项所述的用途，其中，所述受试者是哺乳动物，例如人或鼠。
  19. 用于在受试者中预防和/或治疗自身免疫性疾病或缓解自身免疫性疾病的一种或多种症状、降低抗双链DNA抗体的水平、降低尿蛋白的水平、和/或降低血糖的方法，所述方法包括向由此需要的受试者施用：权利要求1-6任一项所述的分离的多肽或其变体、权利要求7所述的融合蛋白、权利要求8所述的分离的核酸分子、权利要求9所述的载体或权利要求10所述的宿主细胞、或权利要求11或12所述的药物组合物；
    优选地，所述自身免疫性疾病选自系统性红斑狼疮、1型糖尿病、类风湿性关节炎、强直性脊柱炎、多发性硬化症、银屑病、炎症性肠病、溃疡性结肠炎、克罗恩病、重症肌无力或多发性肌炎；
    优选地，所述受试者是哺乳动物，例如人或鼠。
  20. 用于在受试者中预防和/或治疗自身免疫性疾病或缓解自身免疫性疾病的一种或多种症状、降低抗双链DNA抗体的水平、降低尿蛋白的水平、和/或降低血糖的 方法，所述方法包括向由此需要的受试者施用gp96蛋白的C末端结构域(即，C末端同源二聚结构域)或其活性片段或其变体；
    优选地，所述活性片段包含gp96蛋白的第578-713位氨基酸残基；
    优选地，所述活性片段包含：gp96蛋白的第578-713位氨基酸残基、第578-743位氨基酸残基、第578-773位氨基酸残基、第578-803位氨基酸残基、第550-713位氨基酸残基、第550-743位氨基酸残基、或第550-773位氨基酸残基；
    优选地，所述活性片段包含选自下列的氨基酸序列：SEQ ID NOs:31、32、33、37、42、43、44；
    优选地，所述活性片段选自权利要求1-6任一项中所述的分离的多肽；
    优选地，所述变体与其所源自的多肽相异仅在于1个或几个(例如，1个、2个、3个、4个或5个)氨基酸残基的置换、缺失或添加，且保留了其所源自的多肽的生物学功能(例如诱导调节性T细胞活化，不诱导效应T细胞和B细胞活化的活性，预防和/或治疗自身免疫性疾病或缓解自身免疫性疾病的一种或多种症状，降低抗双链DNA抗体的水平，降低尿蛋白的水平，和/或降低血糖)；
    优选地，所述变体与其所源自的多肽相异仅在于1个、2个或3个氨基酸残基的置换、缺失或添加；优选地，所述置换包括将所述氨基酸残基替换为丙氨酸(A)；
    优选地，所述变体包含选自下列的氨基酸序列：SEQ ID NOs:55-62；
    优选地，所述变体选自权利要求1-6任一项中所述的变体；
    优选地，所述自身免疫性疾病选自系统性红斑狼疮、1型糖尿病、类风湿性关节炎、强直性脊柱炎、多发性硬化症、银屑病、炎症性肠病、溃疡性结肠炎、克罗恩病、重症肌无力或多发性肌炎；
    优选地，所述受试者是哺乳动物，例如人或鼠。
PCT/CN2021/119376 2021-02-24 2021-09-18 用于治疗自身免疫性疾病的多肽 WO2022179093A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110205336.1 2021-02-24
CN202110205336.1A CN114957434A (zh) 2021-02-24 2021-02-24 用于治疗自身免疫性疾病的多肽

Publications (1)

Publication Number Publication Date
WO2022179093A1 true WO2022179093A1 (zh) 2022-09-01

Family

ID=82972910

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/119376 WO2022179093A1 (zh) 2021-02-24 2021-09-18 用于治疗自身免疫性疾病的多肽

Country Status (2)

Country Link
CN (1) CN114957434A (zh)
WO (1) WO2022179093A1 (zh)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105749251A (zh) * 2016-04-08 2016-07-13 中国科学院微生物研究所 热休克蛋白gp96在预防和治疗1型糖尿病中的应用
CN105963681A (zh) * 2016-05-09 2016-09-28 中国科学院微生物研究所 热休克蛋白gp96在治疗系统性红斑狼疮中的应用
CN106039287A (zh) * 2016-06-28 2016-10-26 中国科学院微生物研究所 热休克蛋白gp96在治疗类风湿性关节炎中的应用
CN106822869A (zh) * 2017-03-16 2017-06-13 北京热休生物技术有限公司 Def8蛋白及其多肽在治疗与预防癌症中的应用
CN106890315A (zh) * 2017-03-16 2017-06-27 北京热休生物技术有限公司 Apo‑e蛋白及其多肽在治疗与预防癌症中的应用
CN106913863A (zh) * 2017-03-16 2017-07-04 北京热休生物技术有限公司 Nup188蛋白及其多肽在治疗与预防癌症中的应用
CN106943588A (zh) * 2017-03-16 2017-07-14 北京热休生物技术有限公司 热休克蛋白gp96在治疗银屑病中的应用
CN106975072A (zh) * 2017-03-16 2017-07-25 北京热休生物技术有限公司 热休克蛋白gp96在治疗自身免疫性溶血性贫血中的应用
CN106983855A (zh) * 2017-03-16 2017-07-28 北京热休生物技术有限公司 热休克蛋白gp96在治疗重症肌无力症中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011512865A (ja) * 2008-03-13 2011-04-28 コンプジェン リミティッド 新規なｇｐ９６由来ペプチド

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105749251A (zh) * 2016-04-08 2016-07-13 中国科学院微生物研究所 热休克蛋白gp96在预防和治疗1型糖尿病中的应用
CN105963681A (zh) * 2016-05-09 2016-09-28 中国科学院微生物研究所 热休克蛋白gp96在治疗系统性红斑狼疮中的应用
CN106039287A (zh) * 2016-06-28 2016-10-26 中国科学院微生物研究所 热休克蛋白gp96在治疗类风湿性关节炎中的应用
CN106822869A (zh) * 2017-03-16 2017-06-13 北京热休生物技术有限公司 Def8蛋白及其多肽在治疗与预防癌症中的应用
CN106890315A (zh) * 2017-03-16 2017-06-27 北京热休生物技术有限公司 Apo‑e蛋白及其多肽在治疗与预防癌症中的应用
CN106913863A (zh) * 2017-03-16 2017-07-04 北京热休生物技术有限公司 Nup188蛋白及其多肽在治疗与预防癌症中的应用
CN106943588A (zh) * 2017-03-16 2017-07-14 北京热休生物技术有限公司 热休克蛋白gp96在治疗银屑病中的应用
CN106975072A (zh) * 2017-03-16 2017-07-25 北京热休生物技术有限公司 热休克蛋白gp96在治疗自身免疫性溶血性贫血中的应用
CN106983855A (zh) * 2017-03-16 2017-07-28 北京热休生物技术有限公司 热休克蛋白gp96在治疗重症肌无力症中的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN CAIWEI, JIA XIAOJUAN, MENG SONGDONG, LIU WENJUN: "Overview of Gp96 mediated immunity", CHINESE JOURNAL OF BIOTECHNOLOGY, ZHONGGUO KEXUEYUAN WEISHENGWU YANJIUSUO, CHINESE ACADEMY OF SCIENCES, INSTITUTE OF MICROBIOLOGY, CN, vol. 27, no. 5, 25 May 2011 (2011-05-25), CN , pages 704 - 711, XP055962495, ISSN: 1000-3061, DOI: 10.13345/j.cjb.2011.05.002 *
HOTER ABDULLAH, EL-SABBAN MARWAN, NAIM HASSAN: "The HSP90 Family: Structure, Regulation, Function, and Implications in Health and Disease", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 19, no. 9, pages 2560, XP055962492, DOI: 10.3390/ijms19092560 *
PAKRAVAN, N. ET AL.: "Comparison of adjuvant activity of N- and C-terminal domain of gp96 in a Her2-positive breast cancer model", CELL STRESS AND CHAPERONES, 26 February 2011 (2011-02-26), pages 449 - 457, XP019918576, DOI: 10.1007/s12192-011-0258-6 *

Also Published As

Publication number Publication date
CN114957434A (zh) 2022-08-30

Similar Documents

Publication Publication Date Title
US7387886B2 (en) Prion protein dimers useful for vaccination
US6551595B1 (en) Smallpox inhibitor of complement enzymes (SPICE) protein and methods of inhibiting complement activation
CN101896499A (zh) 使用前胰岛肽及其类似物的组合物和方法
US10363306B2 (en) Cytokines and neuroantigens for treatment of immune disorders
JP2002537796A (ja) ヒトグリコシル化酵素
DK1937723T3 (en) Modified chaperonin 10
WO2022179093A1 (zh) 用于治疗自身免疫性疾病的多肽
AU2001285427B2 (en) Stress proteins and peptides and methods of use thereof
US20100173840A1 (en) Pharmaceutical Composition for Treating Autoimmune, Allergic and Inflammatory Diseases and Delivery Method Thereof
JP4422330B2 (ja) 新規な免疫異常性疾患予防・治療用剤
US11098090B2 (en) Mycobacteria tuberculosis chaperonin 60.1 peptides and uses thereof
WO2022247740A1 (zh) 一种多肽及其在制备免疫调节药物中的应用
AU2001285427A1 (en) Stress proteins and peptides and methods of use thereof
WO2012152882A1 (en) Methods and pharmaceutical compositions for the treatment of autoimmune diseases
KR101255682B1 (ko) 신규한 ｍｄ-2 결합 폴리펩타이드 및 이의 용도
US20230272020A1 (en) Modified semaphorin 3a, compositions comprising the same and uses thereof
US20120094935A1 (en) Methods for creating or identifying compounds that bind tumor necrosis factor alpha
WO2017070569A1 (en) Compounds that bind macrophage migration inhibitory factor
WO2024021383A1 (zh) gp96及其在治疗肌萎缩侧索硬化的用途
CN115490764A (zh) Lgals3的表位肽及所述表位肽与热休克蛋白的复合物
JP2007523605A (ja) 細胞毒性が低減された免疫原性ヒトＴＮＦαアナログおよびそれらの製造方法
US20230372434A1 (en) Method of treating fibrosis with a combination therapy
CN115491369A (zh) Pdia3的表位肽及所述表位肽与热休克蛋白的复合物
KR20210071019A (ko) 변형된 MHC 클래스 II DRα1 도메인을 포함하는 재조합 폴리펩타이드 및 이의 사용 방법
EP1652856A1 (en) Stress proteins-derived peptides and method of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21927519

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21927519

Country of ref document: EP

Kind code of ref document: A1